Bloom syndrome

Mendelian MONDO:0008876 Pathograph 37 Show in embeddings browser chromosomal instability syndrome hereditary disease

Bloom syndrome is a rare autosomal recessive chromosome-instability disorder caused by biallelic loss-of-function variants in BLM. BLM is a RecQ helicase that cooperates with TOP3A, RMI1, and RMI2 to dissolve homologous-recombination intermediates without crossover. Loss of this activity causes hyper-recombination, loss of heterozygosity, markedly increased sister-chromatid exchange as a cellular readout, and a striking predisposition to early and multiple cancers. Severe pre- and postnatal growth deficiency, sparse adipose tissue, feeding difficulty and reflux, a narrow facial gestalt, photosensitive telangiectatic skin disease, immune abnormalities, recurrent infections, insulin resistance or diabetes, infertility, pulmonary disease, and hypothyroidism also occur, but their causal links to BLM deficiency are substantially less resolved than the cancer mechanism.

Ask OpenScientist

Ask a research question about Bloom syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
6
Pathophys.
20
Phenotypes
4
Gaps
37
Pathograph
1
Genes
11
Medical Actions
3
Differentials
1
Datasets
1
Trials
1
Models
14
References
1
Deep Research
🏷

Classifications

Harrison's Part
GENETICS ENVIRONMENT DISEASE ONCOLOGY HEMATOLOGY
IUIS Category
combined immunodeficiency with syndromic features
🔗

Mappings

MONDO
MONDO:0008876 Bloom syndrome
skos:exactMatch MONDO
MONDO:0008876 is the primary disease concept for biallelic BLM-related Bloom syndrome.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Bloom syndrome is inherited as an autosomal recessive disorder caused by biallelic pathogenic variants in BLM. When both parents carry a pathogenic variant, each pregnancy has a 25% chance of an affected child.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:20301572 SUPPORT Other
"BSyn is inherited in an autosomal recessive manner."
GeneReviews directly states the inheritance pattern.
PMID:20301572 SUPPORT Other
"each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants and being affected"
GeneReviews supplies the recurrence risk when both parents are carriers.
?

Discussions and Knowledge Gaps

4
Which molecular consequences of BLM loss cause growth restriction, sparse adipose tissue, feeding difficulty and reflux, the narrow facial gestalt, photosensitivity and telangiectasia, immune abnormalities, insulin resistance, infertility, bronchiectasis, and hypothyroidism?
KNOWLEDGE GAP OPEN bloom_nonmalignant_mechanism_gap
Attached to
pathophysiology#Unresolved Nonmalignant Multisystem Consequences
The chromosome-instability-to-cancer branch is experimentally supported, but assigning that same route to every nonmalignant phenotype would exceed current evidence.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Other
"remains unexplained, as do the medical complications of BSyn other than cancer."
GeneReviews explicitly states the central mechanistic gap.
How much do individual components of intensive cancer surveillance improve stage at diagnosis, treatment burden, and survival in Bloom syndrome?
KNOWLEDGE GAP OPEN bloom_surveillance_outcome_gap
Attached to
phenotypes#Neoplasm treatments#Age- and organ-specific cancer surveillance
Current schedules are clinically important consensus guidance, but the disease is exceptionally rare and component-specific outcome evidence is limited.
Show evidence (1 reference)
PMID:30055079 SUPPORT Other
"The purpose of this report is to use information from the BSyn Registry, published literature, and expertise from clinicians and researchers with experience in BSyn to develop recommendations for diagnosis, screening, and treatment"
The consensus paper states the evidence basis for surveillance recommendations.
Do unresolved G-quadruplexes and altered chromatin accessibility materially contribute to human Bloom syndrome manifestations beyond the established hyper-recombination pathway?
EMERGING HYPOTHESIS OPEN bloom_g4_regulatory_hypothesis
Attached to
pathophysiology#Biallelic BLM Loss of Function
A 2026 preprint reports correlated G4, accessibility, and expression changes in cell lines, plus partial phenocopy after G4 stabilization. It is promising but not yet sufficient for promotion into the core clinical mechanism graph.
Show evidence (1 reference)
PMID:41867784 SUPPORT In Vitro
"G4 stabilization partially recapitulated BS-associated molecular phenotypes."
This perturbation result motivates the hypothesis while remaining preclinical and preprint evidence.
Does heterozygous BLM carrier status materially increase cancer risk in defined populations or exposure contexts?
INTERPRETATION OPEN bloom_heterozygote_cancer_risk
Attached to
genetic#BLM
Bloom syndrome itself requires biallelic pathogenic variants. Carrier-risk claims should not be imported into the disease mechanism without population-specific evidence and replication.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"Heterozygotes (carriers) are not at risk of developing BSyn; the cancer risk of heterozygotes as a group remains unclear."
Current GeneReviews preserves the uncertainty while separating carriers from affected people.
⚙

Pathophysiology

6
Biallelic BLM Loss of Function
Biallelic pathogenic variants abolish or severely impair the BLM RecQ helicase. This is the initiating lesion for the chromosome-instability phenotype, while the routes to most nonmalignant manifestations remain unresolved.
BLM hgnc:1058 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves BLM (hgnc:1058). hgnc:1058 is a gene from the HUGO Gene Nomenclature Committee.
BLM RecQ 3'-5' DNA helicase activity GO:0043138 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased BLM RecQ 3'-5' DNA helicase activity, annotated with 3'-5' DNA helicase activity (GO:0043138). GO:0043138 is a molecular function from the Gene Ontology.
Downstream
Failure of BTRR Double-Holliday-Junction Dissolution Loss of BLM disables the BLM-TOP3A-RMI1-RMI2 dissolution complex.
Unresolved Nonmalignant Multisystem Consequences Biallelic BLM loss causes the syndrome's nonmalignant manifestations, but the intervening mechanisms are not established.
Show evidence (1 reference)
PMID:7585968 SUPPORT Human Clinical
"The presence of chain-terminating mutations in the candidate gene in persons with BS proved that it was BLM."
The positional-cloning study established BLM as the causal gene using chain-terminating variants in affected people.
Failure of BTRR Double-Holliday-Junction Dissolution
BLM normally cooperates with TOP3A, RMI1, and RMI2 in the BTRR complex to dissolve double Holliday junctions without crossover. Loss of BLM removes this anti-crossover genome-maintenance activity.
double-strand break repair via homologous recombination GO:0000724 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal double-strand break repair via homologous recombination (GO:0000724). GO:0000724 is a biological process from the Gene Ontology.
Downstream
Mitotic Hyper-Recombination Loss of anti-crossover dissolution permits excessive mitotic crossover.
Show evidence (2 references)
PMID:14685245 SUPPORT In Vitro
"The mechanism, which we term double-junction dissolution, is distinct from classical Holliday junction resolution and prevents exchange of flanking sequences."
The primary biochemical study defines the non-crossover dissolution function lost when BLM is deficient.
PMID:25794620 SUPPORT In Vitro
"Finally, we identify critical residues that mediate interactions between TopBP1 and MDC1, and between BLM and TOP3A/RMI1/RMI2."
Cell-based interaction mapping independently supports BLM association with TOP3A, RMI1, and RMI2.
Mitotic Hyper-Recombination
BLM-deficient cells undergo excessive homologous recombination and mitotic crossover. Elevated sister-chromatid exchange is modeled as a cellular readout of this state rather than as a separate causal driver.
Downstream
Increased Loss of Heterozygosity Excessive interhomolog crossover increases loss of heterozygosity.
Show evidence (1 reference)
PMID:28232778 SUPPORT In Vitro
"The absence of a functional BLM protein causes chromosome instability, excessive homologous recombination, and a greatly increased number of sister chromatid exchanges that are pathognomonic of the syndrome."
The cellular evidence identifies excessive homologous recombination after loss of functional BLM; SCE is retained as its diagnostic readout.
Increased Loss of Heterozygosity
Excessive interhomolog crossover recurrently removes heterozygosity across the genome, increasing the probability that cancer-relevant somatic variants become homozygous.
Downstream
Early-Onset Multicancer Predisposition Increased LOH from mitotic recombination drives tumor susceptibility across tissues.
Show evidence (1 reference)
PMID:21730139 SUPPORT In Vitro
"LOH is increased by fivefold or more, implying significantly increased interhomolog crossing over."
This experiment quantifies the crossover-associated loss-of-heterozygosity intermediate in BLM-deficient cells.
Early-Onset Multicancer Predisposition
Accumulating somatic genome alterations produce a broad, early-onset cancer predisposition affecting hematologic and solid-tumor lineages, often with multiple primary cancers in one person.
Downstream
Neoplasm Genome instability produces the clinical phenotype of early and multiple malignancies.
Show evidence (1 reference)
PMID:35420546 SUPPORT Human Clinical
"Among the 290 individuals in the BSR, 155 (53%) participants developed 251 malignant neoplasms; 100 (65%) were diagnosed with 1 malignancy, whereas the remaining 55 (35%) developed multiple malignancies."
The registry study documents the broad and frequently multiple cancer burden in molecularly defined Bloom syndrome.
Unresolved Nonmalignant Multisystem Consequences
Bloom syndrome has characteristic growth, craniofacial, gastrointestinal, dermatologic, immune, metabolic, reproductive, pulmonary, and thyroid manifestations, but current evidence does not establish a single downstream molecular route from BLM loss to these findings.
Downstream
Prenatal growth restriction BLM deficiency is associated with prenatal growth restriction through unknown intermediates.
Short stature Persistent postnatal growth deficiency produces short stature through unknown intermediates.
Microcephaly Reduced head growth is associated with BLM deficiency through unknown intermediates.
Feeding difficulties Early feeding difficulties are associated with BLM deficiency through unknown intermediates.
Gastroesophageal reflux Gastroesophageal reflux is associated with BLM deficiency through unknown intermediates.
Dolichocephaly The recurrent long, narrow head shape is associated with BLM deficiency through unknown intermediates.
Narrow face The characteristic narrow facial gestalt is associated with BLM deficiency through unknown intermediates.
Adipose tissue loss Sparse subcutaneous adipose tissue is associated with BLM deficiency through unknown intermediates.
Cutaneous photosensitivity The characteristic sun-sensitive rash arises through unknown intermediates.
Telangiectasia Telangiectasia within the characteristic rash is associated with BLM deficiency through unknown intermediates.
Hypogammaglobulinemia Reduced immunoglobulin concentrations arise through unknown intermediates.
Recurrent infections Infection susceptibility is associated with immune abnormalities through incompletely defined intermediates.
Insulin resistance Insulin resistance arises through unknown intermediates.
Diabetes mellitus Early diabetes develops from insulin resistance through incompletely defined intermediates.
Male infertility Male infertility is associated with BLM deficiency through unknown intermediates.
Premature ovarian insufficiency Premature menopause in affected women arises through unknown intermediates.
Bronchiectasis Chronic airway disease and bronchiectasis arise through unknown intermediates.
Hypothyroidism Hypothyroidism is associated with Bloom syndrome through unknown intermediates.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Other
"remains unexplained, as do the medical complications of BSyn other than cancer."
GeneReviews explicitly marks the noncancer mechanisms as unresolved.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Bloom syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

20
Blood 1
Hypogammaglobulinemia VERY_FREQUENT Decreased circulating immunoglobulin concentration HP:0004313 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypogammaglobulinemia, annotated with Decreased circulating immunoglobulin concentration (HP:0004313). HP:0004313 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"the concentration of one or more of the plasma immunoglobulins is usually abnormally low. IgM and IgA levels are most commonly affected."
GeneReviews' "usually" wording supports the very-frequent band and identifies the commonly affected isotypes.
Cardiovascular 1
Telangiectasia VERY_FREQUENT HP:0001009 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Telangiectasia (HP:0001009). HP:0001009 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"It is usually characterized by telangiectasia but in others is described as poikiloderma."
GeneReviews' "usually" wording supports the very-frequent band.
Digestive 2
Feeding difficulties VERY_FREQUENT HP:0011968 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Most parents report that feeding is an issue for their newborns, infants, and young children."
GeneReviews' "most parents" wording supports the very-frequent band.
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Many infants have had gastrostomy tubes placed."
GeneReviews documents that feeding support can include gastrostomy in infancy.
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"The child with BSyn characteristically eats slowly, has a decreased appetite, and eats a limited variety of foods."
GeneReviews supports the characteristic appetite and feeding-pattern features.
Gastroesophageal reflux FREQUENT HP:0002020 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gastroesophageal reflux (HP:0002020). HP:0002020 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Gastroesophageal reflux is common and may contribute to the feeding issues."
GeneReviews' "common" wording supports the frequent band.
Endocrine 2
Diabetes mellitus OCCASIONAL HP:0000819 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diabetes mellitus (HP:0000819). HP:0000819 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Diabetes has been diagnosed in 51 of 294 persons in the Bloom Syndrome Registry (17.3%) at a mean age of 26.2 years (range: 4-48 years)."
The registry frequency supports an occasional classification and early onset.
Hypothyroidism HP:0000821 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypothyroidism (HP:0000821). HP:0000821 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301572 SUPPORT Human Clinical
"Serious medical complications that are more common than in the general population and that also appear at unusually early ages include cancer of a wide variety of types and anatomic sites, diabetes mellitus as a result of insulin resistance, chronic obstructive pulmonary disease, and hypothyroidism."
GeneReviews identifies hypothyroidism among complications that occur at unusually early ages.
Genitourinary 2
Male infertility VERY_FREQUENT HP:0003251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Male infertility (HP:0003251). HP:0003251 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301572 SUPPORT Human Clinical
"men tend to be infertile, with only one confirmed case of paternity."
The summary supports male infertility as a characteristic feature.
Context-specific annotations (1)
MALE
Applies to affected males assessed for infertility.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Most men with BSyn assessed for infertility have had azoospermia or severe oligospermia."
GeneReviews directly describes the male-limited phenotype.
Premature ovarian insufficiency FREQUENT HP:0008209 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Premature ovarian insufficiency (HP:0008209). HP:0008209 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301572 SUPPORT Human Clinical
"Women may be fertile but often have early menopause"
The clinical summary supports premature ovarian insufficiency.
Context-specific annotations (1)
FEMALE
Applies to affected women; fertility can be preserved before early menopause.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Women with BSyn, although often fertile, may enter menopause prematurely."
GeneReviews distinguishes preserved fertility from early ovarian failure.
Head and Neck 3
Microcephaly VERY_FREQUENT HP:0000252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Microcephaly (HP:0000252). HP:0000252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301572 SUPPORT Human Clinical
"Despite their very small head circumference, most affected individuals have normal intellectual ability."
GeneReviews' "most affected individuals" wording supports the very-frequent band while preserving normal cognition as a separate observation.
Narrow face FREQUENT HP:0000275 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Narrow face (HP:0000275). HP:0000275 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"More commonly, the face appears narrow, with underdeveloped malar and mandibular prominences and retrognathia or micrognathia"
GeneReviews' "more commonly" wording supports the frequent band.
Dolichocephaly FREQUENT HP:0000268 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dolichocephaly (HP:0000268). HP:0000268 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"The head shape is often described as long and narrow"
GeneReviews' "often" wording supports the frequent band.
Immune 1
Recurrent infections HP:0002719 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent infections (HP:0002719). HP:0002719 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Parents of children with BSyn report that their affected children have more childhood infections than their sibs and peers"
GeneReviews supports increased childhood infection frequency.
Integument 1
Cutaneous photosensitivity VERY_FREQUENT HP:0000992 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cutaneous photosensitivity (HP:0000992). HP:0000992 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"typically following sun exposure during the first or second year of life, a red, sun-sensitive rash appears on the nose and cheeks"
GeneReviews' "typically" wording supports the very-frequent band and characteristic early timing.
Metabolism 1
Insulin resistance HP:0000855 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Insulin resistance (HP:0000855). HP:0000855 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301572 SUPPORT Human Clinical
"Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, and a high risk for many cancers that occur at an early age."
GeneReviews lists insulin resistance among the defining clinical features.
Musculoskeletal 1
Adipose tissue loss HP:0008887 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Adipose tissue loss (HP:0008887). HP:0008887 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Subcutaneous adipose tissue is sparse throughout childhood and adolescence, but adults may develop central obesity."
GeneReviews directly describes the age-dependent adipose phenotype without supplying a frequency band.
Respiratory 1
Bronchiectasis FREQUENT HP:0002110 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bronchiectasis (HP:0002110). HP:0002110 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Chronic bronchitis and bronchiectasis are common, and pulmonary failure has been the cause of death in six persons."
GeneReviews directly supports the pulmonary phenotype and severity.
Cellular 1
Chromosome instability VERY_FREQUENT Abnormality of chromosome stability HP:0003220 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chromosome instability, annotated with Abnormality of chromosome stability (HP:0003220). HP:0003220 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28232778 SUPPORT In Vitro
"The absence of a functional BLM protein causes chromosome instability, excessive homologous recombination, and a greatly increased number of sister chromatid exchanges that are pathognomonic of the syndrome."
The review identifies the defining cellular phenotype.
Growth 2
Prenatal growth restriction VERY_FREQUENT Intrauterine growth retardation HP:0001511 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Prenatal growth restriction, annotated with Intrauterine growth retardation (HP:0001511). HP:0001511 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301572 SUPPORT Human Clinical
"Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency"
GeneReviews identifies severe prenatal and postnatal growth deficiency as a defining feature.
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"The most consistent clinical feature of BSyn seen throughout all stages of life is growth deficiency affecting height, weight, and head circumference."
The full chapter's "most consistent" wording supports the very-frequent band.
Short stature VERY_FREQUENT HP:0004322 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short stature (HP:0004322). HP:0004322 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"The most consistent clinical feature of BSyn seen throughout all stages of life is growth deficiency affecting height, weight, and head circumference."
GeneReviews characterizes persistent growth deficiency as the most consistent finding.
Neoplasm 1
Neoplasm VERY_FREQUENT HP:0002664 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neoplasm (HP:0002664). HP:0002664 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35420546 SUPPORT Human Clinical
"The cumulative incidence of any malignancy by age 40 was 83%."
Registry follow-up supports a very frequent, age-dependent cancer phenotype.
🧬

Genetic Associations

1
BLM (Biallelic loss-of-function)
Gene: BLM hgnc:1058 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BLM (hgnc:1058). hgnc:1058 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (3 references)
PMID:7585968 SUPPORT Human Clinical
"The presence of chain-terminating mutations in the candidate gene in persons with BS proved that it was BLM."
The gene-discovery study established causal BLM loss-of-function variants in affected individuals.
CGGV:assertion_e0a20b67-5a62-462c-894b-76b60a66e979-2019-04-19T160000.000Z SUPPORT Other
"BLM | HGNC:1058 | Bloom syndrome | MONDO:0008876 | AR | Definitive"
ClinGen classifies the BLM-Bloom syndrome gene-disease relationship as definitive with autosomal recessive inheritance.
PMID:28232778 SUPPORT Human Clinical
"A common founder mutation designated blmAsh is present in about 1 in 100 persons of Eastern European Jewish ancestry, and there are additional recurrent founder mutations among other populations."
The review reports the ancestry-associated blmAsh founder allele while noting other population-specific founders.
🗃️

External Assertions

1
ClinGen BLM–Bloom syndrome gene-disease validity assertion
ClinGen gene disease validity CGGV:assertion_e0a20b67-5a62-462c-894b-76b60a66e979-2019-04-19T160000.000Z
ClinGen classifies the autosomal recessive BLM–Bloom syndrome relationship as definitive.
Show evidence (1 reference)
CGGV:assertion_e0a20b67-5a62-462c-894b-76b60a66e979-2019-04-19T160000.000Z SUPPORT Other
"BLM | HGNC:1058 | Bloom syndrome | MONDO:0008876 | AR | Definitive"
The structured ClinGen assertion supplies the gene, disease, inheritance, and definitive classification.
💊

Medical Actions

11
Nutritional, feeding, and reflux management
Category: Therapeutic Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Use calorie-dense formulas or foods when appropriate, involve gastroenterology or feeding specialists, and treat gastroesophageal reflux as needed.
Target Phenotypes: Feeding difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology. Gastroesophageal reflux HP:0002020 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Gastroesophageal reflux (HP:0002020). HP:0002020 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"Increased-calorie-density formulas and foods may promote weight gain; consultation with gastroenterologist or feeding specialist and treatment for gastroesophageal reflux disease as needed; standard dietary treatment for dyslipidemia."
GeneReviews provides supportive nutritional, feeding-specialist, and reflux-management guidance.
Rigorous sun protection
Category: Therapeutic Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Avoid excessive ultraviolet exposure, use sun-protective clothing and a broad-brimmed hat, wear UV-blocking sunglasses, and apply broad-spectrum sunscreen with SPF 30 or higher.
Mechanism Target:
MODULATES Cutaneous photosensitivity — Reducing ultraviolet exposure decreases provocation and severity of the sun-sensitive rash.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"Skin protection, including avoiding excessive sun exposure"
Avoidance directly reduces the environmental trigger for the phenotype.
Target Phenotypes: Cutaneous photosensitivity HP:0000992 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Cutaneous photosensitivity (HP:0000992). HP:0000992 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"Skin protection, including avoiding excessive sun exposure, sun-protective clothing and broad-brimmed hat, UV-blocking sunglasses, and use of broad-spectrum sunscreen with SPF of at least 30"
GeneReviews specifies a practical ultraviolet-protection regimen.
Immunoglobulin replacement for selected patients
Category: Therapeutic Action: intravenous immunoglobulin therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is intravenous immunoglobulin therapy, annotated with Immunoglobulin Therapy (NCIT:C62710). NCIT:C62710 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunoglobulin Therapy NCIT:C62710
Individuals with recurrent infections and documented humoral immune defects may receive immunoglobulin replacement to reduce infection frequency and severity; this is not a universal treatment for every affected person.
Mechanism Target:
RESTORES Hypogammaglobulinemia — Exogenous immunoglobulin replaces deficient circulating antibody function.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"may be treated with immunoglobulins to decrease frequency and severity of infections."
The clinical recommendation supports functional antibody replacement.
Target Phenotypes: Hypogammaglobulinemia HP:0004313 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypogammaglobulinemia, annotated with Decreased circulating immunoglobulin concentration (HP:0004313). HP:0004313 is a phenotype from the Human Phenotype Ontology. Recurrent infections HP:0002719 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Recurrent infections (HP:0002719). HP:0002719 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"Individuals with recurrent infections and defects in humoral immunity may be treated with immunoglobulins to decrease frequency and severity of infections."
GeneReviews bounds replacement therapy to clinically and immunologically selected patients.
Age- and organ-specific cancer surveillance
Category: Screening Action: cancer screeningNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cancer screening (NCIT:C15406). NCIT:C15406 is a clinical intervention from the NCI Thesaurus. Ontology label: Cancer Screening NCIT:C15406
Intensive surveillance includes Wilms-tumor abdominal ultrasound in early childhood, leukemia/lymphoma symptom review, non-ionizing whole-body MRI from adolescence, early colorectal screening, and early breast MRI. The schedule should follow current predisposition guidance and specialist care.
Show evidence (3 references)
PMID:20301572 SUPPORT Other
"Clinical assessment for hematuria and/or abdominal mass and abdominal ultrasound examination every three months until age eight years for Wilms tumor."
GeneReviews provides a concrete early-childhood component of surveillance.
PMID:39264246 SUPPORT Other
"Recognition of children with genomic instability disorders is important in order to make the proper diagnosis, enable genetic counseling, and inform cancer screening, cancer risk reduction, and choice of anticancer therapy."
The AACR guideline explicitly includes Bloom syndrome in genomic-instability surveillance.
PMID:20301572 SUPPORT Other
"Skin exam with a dermatologist upon recognition of suspicious skin lesions and annually thereafter."
Adds the dermatologic component of surveillance, which is the organ-specific counterpart to the ultraviolet exposure recorded as a risk factor.
Individualized reduced-toxicity cancer therapy
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Cancer treatment is individualized by oncology specialists, commonly with reduced dosage or duration because standard regimens can cause excessive toxicity. Ionizing radiation and alkylating agents are minimized or avoided when clinically feasible; undertreatment is also a risk, so no universal dose reduction is asserted.
Target Phenotypes: Neoplasm HP:0002664 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Neoplasm (HP:0002664). HP:0002664 is a phenotype from the Human Phenotype Ontology.
Show evidence (6 references)
PMID:20301572 SUPPORT Other
"In persons with cancer, modification of chemotherapy dosage and duration per oncologist."
GeneReviews recommends individualized oncologist-directed modification.
PMID:20301572 SUPPORT Other
"Alkylating agents and radiation therapy are considered high risk and are avoided when possible in those with BSyn."
The source supports minimizing particularly hazardous modalities.
PMID:33226170 SUPPORT Other
"We recommend starting at lower doses and escalating as tolerated, with close monitoring for toxicity as further dose modifications may be required in order to complete therapy."
Gives the dosing strategy behind individualized reduced-toxicity therapy, namely starting low, escalating to tolerance, and expecting further modification.
+ 3 more references
Metabolic and thyroid surveillance
Category: Monitoring Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Beginning in childhood, annual fasting glucose, hemoglobin A1c, and thyroid testing support early detection and standard treatment of diabetes and hypothyroidism.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"Annual fasting blood glucose and hemoglobin A1c beginning at age ten years. Annual serum TSH with reflex to thyroxine beginning at age ten years."
GeneReviews specifies annual metabolic and thyroid surveillance from age ten.
Airway-clearance and pulmonary care
Category: Therapeutic Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Recurrent or chronic pulmonary disease is assessed at each visit. Bronchiectasis care can include cough-assist devices, vibration vests, and daily nasal lavage for mucociliary clearance.
Target Phenotypes: Bronchiectasis HP:0002110 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Bronchiectasis (HP:0002110). HP:0002110 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"Cough assist devices, vibration vests, and daily nasal lavage for mucociliary clearance for bronchiectasis."
GeneReviews lists the airway-clearance measures used for bronchiectasis.
Hematopoietic cell transplantation for hematologic malignancy
Category: Therapeutic Action: hematopoietic cell transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hematopoietic cell transplantation (NCIT:C15431). NCIT:C15431 is a clinical intervention from the NCI Thesaurus. Ontology label: Hematopoietic Cell Transplantation NCIT:C15431
Allogeneic transplantation is used for hematologic malignancy in Bloom syndrome, but the reported experience is small and toxicity is substantial, because conditioning regimens deliver exactly the DNA-damaging exposure these patients tolerate poorly. It is a specialist-directed option under active uncertainty rather than a standard-of-care recommendation.
Target Phenotypes: Neoplasm HP:0002664 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Neoplasm (HP:0002664). HP:0002664 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:40641635 SUPPORT Other
"There is limited literature about HSCT and BS for children"
Establishes that transplantation is used in this population while the evidence base for it is acknowledged as thin.
PMID:40641635 REFUTE Human Clinical
"In our experience, one patient underwent HSCT with a myeloablative conditioning regimen but died shortly after transplantation due to treatment-related toxicity, despite being in remission at the time."
A myeloablative transplant in remission ended in treatment-related death, which cuts against transplantation with full-intensity conditioning as a safe option here. One patient, so it bounds enthusiasm rather than establishing a rule.
Multidisciplinary endocrine and metabolic co-management during cancer therapy
Category: Therapeutic Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
The endocrinopathies that are already characteristic of Bloom syndrome, principally insulin-resistant diabetes, dyslipidemia, and hypothyroidism, are destabilized by cancer treatment, and steroid and asparaginase exposure add adrenal insufficiency and severe hypertriglyceridemia. Joint oncology and endocrinology management is recommended for the duration of therapy.
Target Phenotypes: Diabetes mellitus HP:0000819 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Diabetes mellitus (HP:0000819). HP:0000819 is a phenotype from the Human Phenotype Ontology. Hypothyroidism HP:0000821 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypothyroidism (HP:0000821). HP:0000821 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33226170 SUPPORT Other
"A multidisciplinary team of oncologists and endocrinologists is best suited to care for this patient population."
States the co-management recommendation this treatment records.
PMID:33226170 SUPPORT Human Clinical
"Both patients experienced severe toxicities and exacerbation of endocrine comorbidities during chemotherapy."
Supplies the observation that motivates co-management, namely that pre-existing endocrine disease worsened under treatment in both reported patients.
Genetic counseling and reproductive options
Category: Counseling / Informational Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Bloom syndrome is autosomal recessive, so each subsequent sibling has a one-in-four recurrence risk. Once both familial BLM variants are known, prenatal and preimplantation genetic testing are available, and carrier screening panels commonly include the condition. Evaluating at-risk siblings also allows sun avoidance and cancer surveillance to start early.
Show evidence (2 references)
PMID:20301572 SUPPORT Other
"Once the BLM pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing are possible."
Establishes the reproductive testing options this counseling action conveys.
PMID:20301572 SUPPORT Other
"It is appropriate to evaluate sibs of a proband in order to identify as early as possible those who would benefit from avoidance of sun exposure and early surveillance for cancer."
Supports sibling evaluation as an actionable counseling step, and links it to the two interventions this entry records as effective.
Developmental and educational support
Category: Therapeutic Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Developmental services and educational support are provided as needed. Intellectual ability is usually normal in Bloom syndrome, so this is individualized support rather than a universal expectation of developmental delay.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"Developmental services and educational support as needed."
GeneReviews lists developmental and educational support among the management measures, qualified as needed.
🌍

Environmental Factors

3
Ultraviolet radiation exposure
exposure to ultraviolet radiation ECTO:0000006 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to ultraviolet radiation (ECTO:0000006). ECTO:0000006 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Hazard type: PHYSICAL
Route: DERMAL
Duration: LIFETIME
Exposome domain: GENERAL EXTERNAL
Sunlight is the provoking exposure for the characteristic facial erythematous, telangiectatic eruption. Skin is generally unaffected at birth and the rash appears after the first sun exposures of infancy or early childhood, so photoprotection is a standing management recommendation and sun exposure is listed among the circumstances to avoid.
Show evidence (1 reference)
PMID:20301572 SUPPORT Other
"Sun exposure to the face and other exposed skin, particularly in infancy and early childhood, should be avoided."
GeneReviews lists sun exposure among the agents and circumstances to avoid, which treats it as a modifiable exposure in this disease rather than an incidental one.
Mechanism Target:
TRIGGERS Cutaneous photosensitivity — Sun exposure is the proximate provocation for the sun-sensitive facial rash rather than a background aggravating factor, because the skin is generally normal until the first exposures occur.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"typically following sun exposure during the first or second year of life, a red, sun-sensitive rash appears on the nose and cheeks"
GeneReviews ties first appearance of the eruption to the first sun exposures, which supports ultraviolet light as the trigger for this phenotype.
Ionizing radiation exposure
exposure to ionizing radiation ECTO:7000047 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to ionizing radiation (ECTO:7000047). ECTO:7000047 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Hazard type: PHYSICAL
Route: MULTIPLE
Duration: INTERMITTENT
Exposome domain: SPECIFIC EXTERNAL
Diagnostic and therapeutic ionizing radiation is treated as a modifiable exposure. BLM-deficient cells resolve radiation-induced DNA damage poorly, guidance is to minimize radiation exposure and prefer non-ionizing imaging for surveillance, and radiotherapy is avoided when a clinically acceptable alternative exists. Evidence that radiotherapy actually causes second cancers in Bloom syndrome remains indirect.
Show evidence (3 references)
PMID:20301572 SUPPORT Other
"Exposure to ionizing radiation should be minimized."
GeneReviews lists minimizing ionizing radiation among the agents and circumstances to avoid, which is the management consequence of treating it as a risk factor.
PMID:38995367 SUPPORT Human Clinical
"In patients with BS, significant sensitivity to both DNA-damaging chemotherapy (CT) and ionizing radiation complicates the management of neoplasms by exacerbating comorbidities and predisposing to toxicities and poor outcomes."
States the clinical premise for treating ionizing radiation as a hazardous exposure in this disease.
PMID:40641635 REFUTE Human Clinical
"Interestingly, radiotherapy was well tolerated, with no complications in the two patients treated, challenging previous assumptions about its risk in BS"
The largest paediatric series to date found radiotherapy acutely well tolerated, which cuts against a blanket radiation-hazard claim. Two patients cannot establish safety, but the observation is recorded rather than dropped because it is the only direct paediatric evidence on tolerability.
Mechanism Target:
EXACERBATES Early-Onset Multicancer Predisposition — Radiation-induced double-strand breaks add lesions to a genome that already mis-resolves recombination intermediates without BLM, so the exposure adds to an existing predisposition rather than initiating it. EXACERBATES rather than TRIGGERS because the biallelic BLM lesion is what establishes the cancer predisposition.
Show evidence (1 reference)
PMID:38995367 SUPPORT Model Organism
"Irradiated Blm-deficient mice (Blmm3/m3) exhibited an increased risk for tumors, particularly hematological malignancies"
An irradiated Blm-deficient mouse model shows radiation raising tumour risk on a BLM-deficient background, which is the mechanism this edge asserts. Model-organism evidence, so it does not by itself establish the effect in patients.
DNA-damaging antineoplastic agent exposure
exposure to antineoplastic agent ECTO:9001737 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to antineoplastic agent (ECTO:9001737). ECTO:9001737 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Hazard type: CHEMICAL
Route: PARENTERAL
Duration: INTERMITTENT
Exposome domain: SPECIFIC EXTERNAL
Cytotoxic chemotherapy, and alkylating agents in particular, are the iatrogenic exposure of greatest concern once a Bloom syndrome patient develops cancer. Clinicians report severe toxicity at conventional doses and recommend avoiding alkylators, topoisomerase inhibitors, and anthracyclines where the disease allows.
Show evidence (2 references)
PMID:33226170 SUPPORT Other
"we recommend avoidance of the use of alkylating agents, topoisomerases and anthracyclines due to the risks of secondary malignancy and cardiotoxicity."
Names the specific drug classes treated as hazardous exposures in Bloom syndrome and the harms they are avoided for.
PMID:40641635 SUPPORT Other
"Treating cancer in BS patients is challenging due to heightened sensitivity to DNA-damaging therapies, including alkylating agents and radiotherapy"
A national multicentre series states the heightened sensitivity to DNA-damaging therapy that makes this an exposure to manage rather than an ordinary treatment choice.
Mechanism Target:
EXACERBATES Early-Onset Multicancer Predisposition — DNA-damaging cytotoxics are given against a first cancer and add genomic lesions to cells that already mis-resolve recombination intermediates, which is the stated reason for avoiding alkylating agents in this population. Registry acute myeloid leukaemias in Bloom syndrome followed chemotherapy for a prior tumour.
Show evidence (1 reference)
PMID:38995367 SUPPORT Other
"Although there are no evidence-based data linking specific chemotherapeutic agents to an increased risk of secondary malignancies, most treating clinicians recommend against the use of alkylating agents, particularly busulfan, cyclophosphamide, or melphalan, due to their direct interaction with DNA."
Records both the practice recommendation and, in the same sentence, that it rests on mechanism and clinical judgement rather than on comparative outcome data.
🔬

Diagnosis

2
BLM molecular genetic testing
A compatible clinical presentation is confirmed by identifying biallelic pathogenic or likely pathogenic BLM variants. Sequence analysis should be complemented by deletion/duplication analysis when only one or no causal variant is found.
molecular genetic testing NCIT:C19770 NCI Thesaurus (NCIT)
Show evidence (3 references)
PMID:20301572 SUPPORT Other
"The diagnosis of BSyn is established in a proband with characteristic clinical features and biallelic pathogenic variants in BLM identified by molecular genetic testing."
Current GeneReviews makes biallelic pathogenic BLM variants the diagnostic standard.
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Other
"If only one or no variant is detected by the sequencing method used"
GeneReviews defines when sequence analysis should be followed by another method.
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Other
"to detect exon and whole-gene deletions or duplications."
GeneReviews specifies the variants sought by follow-up deletion/duplication analysis.
Sister-chromatid-exchange analysis
Specialized cytogenetic analysis can show the highly elevated sister-chromatid-exchange signature and is useful when molecular testing is inconclusive. It is adjunctive, not independently diagnostic, because RMI1-, RMI2-, and TOP3A-related disorders can also increase SCEs.
cytogenetic analysis NCIT:C18280 NCI Thesaurus (NCIT)
Show evidence (4 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT In Vitro
"Increased frequency of SCEs is demonstrable in BSyn cultured cells (including lymphocytes, fibroblasts, and amniocytes) allowed to proliferate in a medium containing 5-bromo-2'-deoxyuridine (BrdU)."
GeneReviews documents the characteristic SCE finding in cultured patient cells.
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Other
"SCE analysis may be a useful adjunct for diagnosis of BSyn"
GeneReviews explicitly positions SCE analysis as an adjunctive test.
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Other
"Increased SCEs are not unique to BSyn."
GeneReviews states the cellular finding is not specific to Bloom syndrome.
+ 1 more reference
📈

Progression

4
Prenatal and persistent growth deficiency
Age: Prenatal onset through adulthood
Reduced fetal growth affects weight, length, and head circumference and persists through childhood and adult life.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"The most consistent clinical feature of BSyn seen throughout all stages of life is growth deficiency affecting height, weight, and head circumference."
GeneReviews describes the lifelong growth trajectory.
Sun-triggered cutaneous disease
Age: Usually first or second year of life onward
Skin is generally normal at birth; a facial erythematous, telangiectatic, sun-sensitive eruption commonly appears after early-childhood sun exposure.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"typically following sun exposure during the first or second year of life, a red, sun-sensitive rash appears on the nose and cheeks"
GeneReviews defines the usual timing and distribution of the rash.
Early and multiple malignancies
Age: Across the lifespan, with high cumulative incidence by age 40
Many cancer types occur at unusually early ages, and multiple primary malignancies are common.
Show evidence (2 references)
PMID:20301572 SUPPORT Human Clinical
"Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, and a high risk for many cancers that occur at an early age."
GeneReviews supports the unusually early and broad cancer risk without asserting a specific childhood tumor sequence.
PMID:35420546 SUPPORT Human Clinical
"100 (65%) were diagnosed with 1 malignancy, whereas the remaining 55 (35%) developed multiple malignancies."
The registry directly documents multiple primary cancers.
Adult endocrine and pulmonary complications
Age: Childhood through adulthood
Insulin-resistant diabetes, hypothyroidism, and chronic pulmonary disease can emerge early relative to the general population and require lifelong surveillance.
Show evidence (1 reference)
PMID:20301572 SUPPORT Human Clinical
"Serious medical complications that are more common than in the general population and that also appear at unusually early ages include cancer of a wide variety of types and anatomic sites, diabetes mellitus as a result of insulin resistance, chronic obstructive pulmonary disease, and hypothyroidism."
GeneReviews describes the later multisystem burden.
🌍

Epidemiology

1
Globally rare disorder with an Ashkenazi Jewish founder allele
Bloom syndrome is rare in all populations. The common blmAsh founder allele occurs in about one in 100 people of Eastern European Jewish ancestry, but carrier frequency is not disease prevalence.
Show evidence (2 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Human Clinical
"Although rare in all populations"
GeneReviews establishes rarity without implying a quantitative global prevalence estimate.
PMID:28232778 SUPPORT Human Clinical
"A common founder mutation designated blmAsh is present in about 1 in 100 persons of Eastern European Jewish ancestry, and there are additional recurrent founder mutations among other populations."
The Bloom syndrome review supplies the ancestry-specific carrier frequency and founder-allele context.
⚖️

Clinical Burden

High
Cancer is common, early, and frequently multiple; immune, metabolic, and pulmonary complications add morbidity, and registry median survival remains markedly shortened.
Show evidence (1 reference)
PMID:35420546 SUPPORT Human Clinical
"The cumulative incidence of any malignancy by age 40 was 83%. The median survival for all participants in the BSR was 36.2 years."
Registry estimates support a high-burden classification.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Bloom syndrome:

Fanconi anemia MONDO:0019391
Overlapping Features Fanconi anemia overlaps with Bloom syndrome through chromosome instability, cancer predisposition, pigmentary change, growth deficiency, and reduced fertility. Skeletal malformations and progressive bone-marrow failure favor Fanconi anemia.
Distinguishing Features
  • Markedly elevated sister-chromatid exchange favors Bloom syndrome.
  • Bone marrow failure and congenital radial-ray anomalies favor Fanconi anemia.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Other
"Bone marrow failure"
The GeneReviews differential table identifies bone-marrow failure as a key feature favoring Fanconi anemia.
Nijmegen breakage syndrome MONDO:0009623
Overlapping Features Nijmegen breakage syndrome is another DNA-repair disorder with growth deficiency, genomic instability, immunodeficiency, and lymphoid cancer predisposition. Declining intellectual performance and absence of telangiectasias distinguish it from the usual Bloom presentation.
Distinguishing Features
  • Elevated sister-chromatid exchange and a sun-sensitive malar rash favor Bloom syndrome.
  • Declining intellectual performance and lymphoid-predominant malignancy favor Nijmegen breakage syndrome.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Other
"Decline in intellectual performance"
GeneReviews identifies declining intellectual performance as a feature favoring Nijmegen breakage syndrome.
Rothmund-Thomson syndrome MONDO:0010002
Overlapping Features RECQL4-related Rothmund-Thomson syndrome overlaps through small stature and cancer susceptibility, but true poikiloderma, alopecia, juvenile cataracts, and premature-aging features favor that diagnosis.
Distinguishing Features
  • A sun-sensitive facial rash and highly elevated sister-chromatid exchange favor Bloom syndrome.
  • True poikiloderma, juvenile cataracts, and premature aging favor Rothmund-Thomson syndrome.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/ SUPPORT Other
"True poikiloderma (not sun-sensitive rash)"
GeneReviews distinguishes true poikiloderma in RECQL4 disease from the Bloom sun-sensitive rash.
📊

Related Datasets

1
G-quadruplexes regulate chromatin accessibility and gene expression in Bloom Syndrome [RNA-seq] geo:GSE283485
Public RNA-seq series containing 24 samples from BLM-deficient and wild-type lymphoblastoid and fibroblast cell lines, with wild-type pyridostatin and vehicle perturbations. The associated preprint also reports ATAC-seq and G4 ChIP-seq; the data support an emerging regulatory hypothesis rather than a validated explanation for the clinical syndrome.
human BULK RNA SEQ n=24
Conditions: BLM-deficient lymphoblastoid cell lines Wild-type lymphoblastoid cell lines BLM-deficient fibroblast cell lines Wild-type fibroblast cell lines Pyridostatin-treated wild-type cells Vehicle-treated wild-type cells
PMID:41867784
Show evidence (1 reference)
PMID:41867784 SUPPORT In Vitro
"Here, we profiled chromatin accessibility and gene expression using ATAC-seq and RNA-seq and mapped endogenous G4 by ChIP-seq in wild type (WT) and BS cell lines."
The associated preprint describes the molecular profiling represented by the public series.
🔬

Clinical Trials

1
NCT00021437 NOT_APPLICABLE COMPLETED
Historical observational Bloom Syndrome Registry and laboratory protocol following affected families, documenting cancers and studying chromosomes and mutations in blood or skin-derived cells. It is not an interventional efficacy trial and does not represent a current disease-modifying therapy.
Show evidence (1 reference)
clinicaltrials:NCT00021437 SUPPORT Human Clinical
"We are defining the clinical syndrome and at the same time are studying cells from affected families in the experimental laboratory."
The official record describes combined registry observation and laboratory investigation.
🐁

Animal Models

1
Blm-deficient Bloom mouse Mus musculus
Viable Blm-deficient mice develop diverse cancers and show increased mitotic recombination and loss of heterozygosity. The model supplies in-vivo causal evidence for the cancer branch but does not establish mechanisms for human growth, immune, dermatologic, or endocrine manifestations.
Diverse malignancies Increased mitotic recombination Loss of heterozygosity
Species
Mus musculus
Genotype
Blm-deficient Bloom mouse
Genes
Blm MGI:107573 Mouse Genome Informatics (MGI) Relation: this experimental model concerns this gene This experimental model concerns Blm (MGI:107573). MGI:107573 is a gene from Mouse Genome Informatics.
Show evidence (2 references)
PMID:11101838 SUPPORT Model Organism
"Using embryonic stem cell technology, we have generated viable Bloom mice that are prone to a wide variety of cancers."
The primary model paper establishes viability and broad cancer predisposition.
PMID:11101838 SUPPORT Model Organism
"Cell lines from these mice show elevations in the rates of mitotic recombination."
The model reproduces the central cellular recombination phenotype.
{ }

Source YAML

click to show 
name: Bloom syndrome
creation_date: '2026-04-11T19:38:25Z'
category: Mendelian
parents:
- chromosomal instability syndrome
- hereditary disease
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:20301572
      reference_title: "Bloom Syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The diagnosis of BSyn is established in a proband with characteristic clinical features and biallelic pathogenic variants in BLM identified by molecular genetic testing."
      explanation: GeneReviews defines Bloom syndrome as a biallelic BLM disorder.
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: PMID:35420546
      reference_title: "Age of first cancer diagnosis and survival in Bloom syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Among the 290 individuals in the BSR, 155 (53%) participants developed 251 malignant neoplasms"
      explanation: Registry data establish malignancy as a central clinical domain.
  iuis_category:
    classification_value: combined immunodeficiency with syndromic features
    notes: >-
      IUIS 2022 classification of inborn errors of immunity (Tangye et al.,
      PMID:35748970), Table 2 "Combined immunodeficiencies with associated or
      syndromic features", section 2 "DNA Repair Defects Other Than Those
      Listed in Table 1", row "Bloom syndrome" (gene BLM, AR, OMIM 604610).
    evidence:
    - reference: PMID:35748970
      reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Bloom syndrome BLM AR 604610 Normal Normal Low Short stature, dysmorphic facies sun-sensitive erythema; marrow failure; leukemia, lymphoma; chromosomal instability"
      explanation: >-
        Table 2 section 2 row identifying Bloom syndrome (BLM) among combined
        immunodeficiencies with associated or syndromic features, with low Ig
        and the syndromic features column; the quote joins the row's wrapped
        lines in the cached PDF extraction.
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0008876
      label: Bloom syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: MONDO:0008876 is the primary disease concept for biallelic BLM-related Bloom syndrome.
external_assertions:
- name: ClinGen BLM–Bloom syndrome gene-disease validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_e0a20b67-5a62-462c-894b-76b60a66e979-2019-04-19T160000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_e0a20b67-5a62-462c-894b-76b60a66e979-2019-04-19T160000.000Z
  description: ClinGen classifies the autosomal recessive BLM–Bloom syndrome relationship as definitive.
  evidence:
  - reference: CGGV:assertion_e0a20b67-5a62-462c-894b-76b60a66e979-2019-04-19T160000.000Z
    reference_title: "BLM / Bloom syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "BLM | HGNC:1058 | Bloom syndrome | MONDO:0008876 | AR | Definitive"
    explanation: The structured ClinGen assertion supplies the gene, disease, inheritance, and definitive classification.
description: >-
  Bloom syndrome is a rare autosomal recessive chromosome-instability disorder
  caused by biallelic loss-of-function variants in BLM. BLM is a RecQ helicase
  that cooperates with TOP3A, RMI1, and RMI2 to dissolve homologous-recombination
  intermediates without crossover. Loss of this activity causes
  hyper-recombination, loss of heterozygosity, markedly increased
  sister-chromatid exchange as a cellular readout, and a striking predisposition
  to early and multiple cancers. Severe pre- and postnatal growth deficiency,
  sparse adipose tissue, feeding difficulty and reflux, a narrow facial gestalt,
  photosensitive telangiectatic skin disease, immune abnormalities, recurrent
  infections, insulin resistance or diabetes, infertility, pulmonary disease,
  and hypothyroidism also occur, but their causal links to BLM deficiency are
  substantially less resolved than the cancer mechanism.
disease_term:
  preferred_term: Bloom syndrome
  term:
    id: MONDO:0008876
    label: Bloom syndrome
synonyms:
- Bloom's syndrome
- BSyn
- Congenital telangiectatic erythema
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Bloom syndrome is inherited as an autosomal recessive disorder caused by
    biallelic pathogenic variants in BLM. When both parents carry a pathogenic
    variant, each pregnancy has a 25% chance of an affected child.
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "BSyn is inherited in an autosomal recessive manner."
    explanation: GeneReviews directly states the inheritance pattern.
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants and being affected"
    explanation: GeneReviews supplies the recurrence risk when both parents are carriers.
epidemiology:
- name: Globally rare disorder with an Ashkenazi Jewish founder allele
  description: >-
    Bloom syndrome is rare in all populations. The common blmAsh founder allele
    occurs in about one in 100 people of Eastern European Jewish ancestry, but
    carrier frequency is not disease prevalence.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although rare in all populations"
    explanation: GeneReviews establishes rarity without implying a quantitative global prevalence estimate.
  - reference: PMID:28232778
    reference_title: "Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A common founder mutation designated blmAsh is present in about 1 in 100 persons of Eastern European Jewish ancestry, and there are additional recurrent founder mutations among other populations."
    explanation: The Bloom syndrome review supplies the ancestry-specific carrier frequency and founder-allele context.
progression:
- phase: Prenatal and persistent growth deficiency
  age_range: Prenatal onset through adulthood
  notes: >-
    Reduced fetal growth affects weight, length, and head circumference and
    persists through childhood and adult life.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most consistent clinical feature of BSyn seen throughout all stages of life is growth deficiency affecting height, weight, and head circumference."
    explanation: GeneReviews describes the lifelong growth trajectory.
- phase: Sun-triggered cutaneous disease
  age_range: Usually first or second year of life onward
  notes: >-
    Skin is generally normal at birth; a facial erythematous, telangiectatic,
    sun-sensitive eruption commonly appears after early-childhood sun exposure.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "typically following sun exposure during the first or second year of life, a red, sun-sensitive rash appears on the nose and cheeks"
    explanation: GeneReviews defines the usual timing and distribution of the rash.
- phase: Early and multiple malignancies
  age_range: Across the lifespan, with high cumulative incidence by age 40
  notes: >-
    Many cancer types occur at unusually early ages, and multiple primary
    malignancies are common.
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, and a high risk for many cancers that occur at an early age."
    explanation: GeneReviews supports the unusually early and broad cancer risk without asserting a specific childhood tumor sequence.
  - reference: PMID:35420546
    reference_title: "Age of first cancer diagnosis and survival in Bloom syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "100 (65%) were diagnosed with 1 malignancy, whereas the remaining 55 (35%) developed multiple malignancies."
    explanation: The registry directly documents multiple primary cancers.
- phase: Adult endocrine and pulmonary complications
  age_range: Childhood through adulthood
  notes: >-
    Insulin-resistant diabetes, hypothyroidism, and chronic pulmonary disease
    can emerge early relative to the general population and require lifelong
    surveillance.
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serious medical complications that are more common than in the general population and that also appear at unusually early ages include cancer of a wide variety of types and anatomic sites, diabetes mellitus as a result of insulin resistance, chronic obstructive pulmonary disease, and hypothyroidism."
    explanation: GeneReviews describes the later multisystem burden.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    Cancer is common, early, and frequently multiple; immune, metabolic, and
    pulmonary complications add morbidity, and registry median survival remains
    markedly shortened.
  evidence:
  - reference: PMID:35420546
    reference_title: "Age of first cancer diagnosis and survival in Bloom syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cumulative incidence of any malignancy by age 40 was 83%. The median survival for all participants in the BSR was 36.2 years."
    explanation: Registry estimates support a high-burden classification.
pathophysiology:
- name: Biallelic BLM Loss of Function
  description: >-
    Biallelic pathogenic variants abolish or severely impair the BLM RecQ
    helicase. This is the initiating lesion for the chromosome-instability
    phenotype, while the routes to most nonmalignant manifestations remain
    unresolved.
  genes:
  - preferred_term: BLM
    term:
      id: hgnc:1058
      label: BLM
  molecular_functions:
  - preferred_term: BLM RecQ 3'-5' DNA helicase activity
    term:
      id: GO:0043138
      label: 3'-5' DNA helicase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:7585968
    reference_title: "The Bloom's syndrome gene product is homologous to RecQ helicases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presence of chain-terminating mutations in the candidate gene in persons with BS proved that it was BLM."
    explanation: >-
      The positional-cloning study established BLM as the causal gene using
      chain-terminating variants in affected people.
  downstream:
  - target: Failure of BTRR Double-Holliday-Junction Dissolution
    description: >-
      Loss of BLM disables the BLM-TOP3A-RMI1-RMI2 dissolution complex.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:14685245
      reference_title: "The Bloom's syndrome helicase suppresses crossing over during homologous recombination."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "BLM and hTOPO IIIalpha together effect the resolution of a recombination intermediate containing a double Holliday junction."
      explanation: The biochemical study directly demonstrates the BLM-dependent dissolution reaction.
  - target: Unresolved Nonmalignant Multisystem Consequences
    description: >-
      Biallelic BLM loss causes the syndrome's nonmalignant manifestations, but
      the intervening mechanisms are not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "remains unexplained, as do the medical complications of BSyn other than cancer."
      explanation: GeneReviews explicitly identifies this as an unresolved mechanistic branch.
- name: Failure of BTRR Double-Holliday-Junction Dissolution
  description: >-
    BLM normally cooperates with TOP3A, RMI1, and RMI2 in the BTRR complex to
    dissolve double Holliday junctions without crossover. Loss of BLM removes
    this anti-crossover genome-maintenance activity.
  biological_processes:
  - preferred_term: double-strand break repair via homologous recombination
    modifier: ABNORMAL
    term:
      id: GO:0000724
      label: double-strand break repair via homologous recombination
  evidence:
  - reference: PMID:14685245
    reference_title: "The Bloom's syndrome helicase suppresses crossing over during homologous recombination."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The mechanism, which we term double-junction dissolution, is distinct from classical Holliday junction resolution and prevents exchange of flanking sequences."
    explanation: >-
      The primary biochemical study defines the non-crossover dissolution
      function lost when BLM is deficient.
  - reference: PMID:25794620
    reference_title: "TopBP1 interacts with BLM to maintain genome stability but is dispensable for preventing BLM degradation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Finally, we identify critical residues that mediate interactions between TopBP1 and MDC1, and between BLM and TOP3A/RMI1/RMI2."
    explanation: Cell-based interaction mapping independently supports BLM association with TOP3A, RMI1, and RMI2.
  downstream:
  - target: Mitotic Hyper-Recombination
    description: Loss of anti-crossover dissolution permits excessive mitotic crossover.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:14685245
      reference_title: "The Bloom's syndrome helicase suppresses crossing over during homologous recombination."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The mechanism, which we term double-junction dissolution, is distinct from classical Holliday junction resolution and prevents exchange of flanking sequences."
      explanation: The primary biochemical study shows that BLM-dependent dissolution prevents crossover exchange.
- name: Mitotic Hyper-Recombination
  description: >-
    BLM-deficient cells undergo excessive homologous recombination and mitotic
    crossover. Elevated sister-chromatid exchange is modeled as a cellular
    readout of this state rather than as a separate causal driver.
  evidence:
  - reference: PMID:28232778
    reference_title: "Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The absence of a functional BLM protein causes chromosome instability, excessive homologous recombination, and a greatly increased number of sister chromatid exchanges that are pathognomonic of the syndrome.
    explanation: >-
      The cellular evidence identifies excessive homologous recombination after
      loss of functional BLM; SCE is retained as its diagnostic readout.
  downstream:
  - target: Increased Loss of Heterozygosity
    description: Excessive interhomolog crossover increases loss of heterozygosity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21730139
      reference_title: "Interhomolog recombination and loss of heterozygosity in wild-type and Bloom syndrome helicase (BLM)-deficient mammalian cells."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "LOH is increased by fivefold or more, implying significantly increased interhomolog crossing over."
      explanation: BLM-deficient mammalian cells directly show increased crossover-associated LOH.
- name: Increased Loss of Heterozygosity
  description: >-
    Excessive interhomolog crossover recurrently removes heterozygosity across
    the genome, increasing the probability that cancer-relevant somatic variants
    become homozygous.
  evidence:
  - reference: PMID:21730139
    reference_title: "Interhomolog recombination and loss of heterozygosity in wild-type and Bloom syndrome helicase (BLM)-deficient mammalian cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "LOH is increased by fivefold or more, implying significantly increased interhomolog crossing over."
    explanation: >-
      This experiment quantifies the crossover-associated loss-of-heterozygosity
      intermediate in BLM-deficient cells.
  downstream:
  - target: Early-Onset Multicancer Predisposition
    description: Increased LOH from mitotic recombination drives tumor susceptibility across tissues.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:11101838
      reference_title: "Cancer predisposition caused by elevated mitotic recombination in Bloom mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "the increased rate of loss of heterozygosity (LOH) resulting from mitotic recombination in vivo constitutes the underlying mechanism causing tumour susceptibility in these mice."
      explanation: The Bloom mouse provides in-vivo causal evidence connecting mitotic recombination and LOH to cancer.
- name: Early-Onset Multicancer Predisposition
  description: >-
    Accumulating somatic genome alterations produce a broad, early-onset cancer
    predisposition affecting hematologic and solid-tumor lineages, often with
    multiple primary cancers in one person.
  evidence:
  - reference: PMID:35420546
    reference_title: "Age of first cancer diagnosis and survival in Bloom syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among the 290 individuals in the BSR, 155 (53%) participants developed 251 malignant neoplasms; 100 (65%) were diagnosed with 1 malignancy, whereas the remaining 55 (35%) developed multiple malignancies."
    explanation: >-
      The registry study documents the broad and frequently multiple cancer
      burden in molecularly defined Bloom syndrome.
  downstream:
  - target: Neoplasm
    description: Genome instability produces the clinical phenotype of early and multiple malignancies.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35420546
      reference_title: "Age of first cancer diagnosis and survival in Bloom syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The cumulative incidence of any malignancy by age 40 was 83%."
      explanation: Registry follow-up quantifies the clinical cancer-predisposition phenotype.
- name: Unresolved Nonmalignant Multisystem Consequences
  description: >-
    Bloom syndrome has characteristic growth, craniofacial, gastrointestinal,
    dermatologic, immune, metabolic, reproductive, pulmonary, and thyroid
    manifestations, but current evidence does not establish a single downstream
    molecular route from BLM loss to these findings.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "remains unexplained, as do the medical complications of BSyn other than cancer."
    explanation: GeneReviews explicitly marks the noncancer mechanisms as unresolved.
  downstream:
  - target: Prenatal growth restriction
    description: BLM deficiency is associated with prenatal growth restriction through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence: &growth_edge_evidence
    - reference: PMID:20301572
      reference_title: "Bloom Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency"
      explanation: The clinical association is strong, but the intervening mechanism is unresolved.
  - target: Short stature
    description: Persistent postnatal growth deficiency produces short stature through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence: *growth_edge_evidence
  - target: Microcephaly
    description: Reduced head growth is associated with BLM deficiency through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301572
      reference_title: "Bloom Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Despite their very small head circumference, most affected individuals have normal intellectual ability."
      explanation: The human phenotype is well described, while its molecular route is unknown.
  - target: Feeding difficulties
    description: Early feeding difficulties are associated with BLM deficiency through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Most parents report that feeding is an issue for their newborns, infants, and young children."
      explanation: The human feeding phenotype is common, while its molecular route from BLM loss is unknown.
  - target: Gastroesophageal reflux
    description: Gastroesophageal reflux is associated with BLM deficiency through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Gastroesophageal reflux is common and may contribute to the feeding issues."
      explanation: The human gastrointestinal phenotype is documented, while its molecular route from BLM loss is unknown.
  - target: Dolichocephaly
    description: The recurrent long, narrow head shape is associated with BLM deficiency through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The head shape is often described as long and narrow"
      explanation: GeneReviews documents the recurrent cranial shape while its molecular route remains unknown.
  - target: Narrow face
    description: The characteristic narrow facial gestalt is associated with BLM deficiency through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "More commonly, the face appears narrow, with underdeveloped malar and mandibular prominences and retrognathia or micrognathia"
      explanation: GeneReviews documents the recurrent facial gestalt but does not assign a molecular route.
  - target: Adipose tissue loss
    description: Sparse subcutaneous adipose tissue is associated with BLM deficiency through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Subcutaneous adipose tissue is sparse throughout childhood and adolescence, but adults may develop central obesity."
      explanation: GeneReviews documents the human adipose phenotype but does not assign a molecular route.
  - target: Cutaneous photosensitivity
    description: The characteristic sun-sensitive rash arises through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301572
      reference_title: "Bloom Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, and a high risk for many cancers that occur at an early age."
      explanation: The association is characteristic, but a causal molecular route is not established.
  - target: Telangiectasia
    description: Telangiectasia within the characteristic rash is associated with BLM deficiency through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "It is usually characterized by telangiectasia but in others is described as poikiloderma."
      explanation: GeneReviews documents the human cutaneous feature but does not assign a molecular route.
  - target: Hypogammaglobulinemia
    description: Reduced immunoglobulin concentrations arise through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the concentration of one or more of the plasma immunoglobulins is usually abnormally low. IgM and IgA levels are most commonly affected."
      explanation: GeneReviews documents the immune phenotype but not its molecular path.
  - target: Recurrent infections
    description: Infection susceptibility is associated with immune abnormalities through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Parents of children with BSyn report that their affected children have more childhood infections than their sibs and peers"
      explanation: The clinical association is documented, while immune mechanisms are variable.
  - target: Insulin resistance
    description: Insulin resistance arises through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301572
      reference_title: "Bloom Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, and a high risk for many cancers that occur at an early age."
      explanation: Insulin resistance is characteristic, but its molecular route from BLM loss is unresolved.
  - target: Diabetes mellitus
    description: Early diabetes develops from insulin resistance through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Diabetes has been diagnosed in 51 of 294 persons in the Bloom Syndrome Registry (17.3%) at a mean age of 26.2 years (range: 4-48 years)."
      explanation: Registry data establish the complication, but the BLM-to-insulin-resistance route is unknown.
  - target: Male infertility
    description: Male infertility is associated with BLM deficiency through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Most men with BSyn assessed for infertility have had azoospermia or severe oligospermia."
      explanation: The reproductive phenotype is strong, while its precise mechanistic chain is unresolved.
  - target: Premature ovarian insufficiency
    description: Premature menopause in affected women arises through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Women with BSyn, although often fertile, may enter menopause prematurely."
      explanation: The association supports ovarian insufficiency while leaving its molecular route unresolved.
  - target: Bronchiectasis
    description: Chronic airway disease and bronchiectasis arise through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Chronic bronchitis and bronchiectasis are common, and pulmonary failure has been the cause of death in six persons."
      explanation: GeneReviews documents the pulmonary phenotype without assigning a molecular mechanism.
  - target: Hypothyroidism
    description: Hypothyroidism is associated with Bloom syndrome through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301572
      reference_title: "Bloom Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Serious medical complications that are more common than in the general population and that also appear at unusually early ages include cancer of a wide variety of types and anatomic sites, diabetes mellitus as a result of insulin resistance, chronic obstructive pulmonary disease, and hypothyroidism."
      explanation: GeneReviews identifies hypothyroidism as an early clinical complication but does not assign a causal molecular route.
phenotypes:
- name: Chromosome instability
  category: Cellular
  frequency: VERY_FREQUENT
  description: >-
    Cultured cells show strikingly elevated sister-chromatid exchanges and a
    broader chromosome-instability phenotype.
  phenotype_term:
    preferred_term: Chromosome instability
    term:
      id: HP:0003220
      label: Abnormality of chromosome stability
  reports_on:
  - target: Mitotic Hyper-Recombination
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Elevated sister-chromatid exchange in cultured cells is a diagnostic
      readout of the hyper-recombination state, not a separate causal driver.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Increased frequency of SCEs is demonstrable in BSyn cultured cells (including lymphocytes, fibroblasts, and amniocytes) allowed to proliferate in a medium containing 5-bromo-2'-deoxyuridine (BrdU)."
      explanation: GeneReviews documents elevated SCE in cultured patient cells as the cellular diagnostic readout.
  evidence:
  - reference: PMID:28232778
    reference_title: "Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The absence of a functional BLM protein causes chromosome instability, excessive homologous recombination, and a greatly increased number of sister chromatid exchanges that are pathognomonic of the syndrome."
    explanation: The review identifies the defining cellular phenotype.
- name: Prenatal growth restriction
  category: Growth
  frequency: VERY_FREQUENT
  description: >-
    Growth deficiency begins prenatally, with affected fetuses typically small
    for gestational age.
  phenotype_term:
    preferred_term: Prenatal growth restriction
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency"
    explanation: GeneReviews identifies severe prenatal and postnatal growth deficiency as a defining feature.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most consistent clinical feature of BSyn seen throughout all stages of life is growth deficiency affecting height, weight, and head circumference."
    explanation: The full chapter's "most consistent" wording supports the very-frequent band.
- name: Short stature
  category: Growth
  frequency: VERY_FREQUENT
  description: >-
    Persistent postnatal growth deficiency affects linear growth throughout
    childhood and adulthood.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most consistent clinical feature of BSyn seen throughout all stages of life is growth deficiency affecting height, weight, and head circumference."
    explanation: GeneReviews characterizes persistent growth deficiency as the most consistent finding.
- name: Microcephaly
  category: Growth
  frequency: VERY_FREQUENT
  description: >-
    Head circumference is persistently below normal, although intellectual
    ability is usually preserved.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite their very small head circumference, most affected individuals have normal intellectual ability."
    explanation: GeneReviews' "most affected individuals" wording supports the very-frequent band while preserving normal cognition as a separate observation.
- name: Feeding difficulties
  category: Gastrointestinal
  frequency: VERY_FREQUENT
  description: >-
    Feeding problems commonly begin in infancy or early childhood and can include
    slow eating, reduced appetite, restricted food variety, and need for enteral
    support in some affected children.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most parents report that feeding is an issue for their newborns, infants, and young children."
    explanation: GeneReviews' "most parents" wording supports the very-frequent band.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Many infants have had gastrostomy tubes placed."
    explanation: GeneReviews documents that feeding support can include gastrostomy in infancy.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The child with BSyn characteristically eats slowly, has a decreased appetite, and eats a limited variety of foods."
    explanation: GeneReviews supports the characteristic appetite and feeding-pattern features.
- name: Gastroesophageal reflux
  category: Gastrointestinal
  frequency: FREQUENT
  description: >-
    Gastroesophageal reflux is a common contributor to early feeding problems.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gastroesophageal reflux is common and may contribute to the feeding issues."
    explanation: GeneReviews' "common" wording supports the frequent band.
- name: Narrow face
  category: Craniofacial
  frequency: FREQUENT
  description: >-
    A narrow face with underdeveloped malar and mandibular prominences is a
    recurrent facial gestalt, often with retrognathia or micrognathia.
  phenotype_term:
    preferred_term: Narrow face
    term:
      id: HP:0000275
      label: Narrow face
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More commonly, the face appears narrow, with underdeveloped malar and mandibular prominences and retrognathia or micrognathia"
    explanation: GeneReviews' "more commonly" wording supports the frequent band.
- name: Dolichocephaly
  category: Craniofacial
  frequency: FREQUENT
  description: >-
    The head shape is often long and narrow.
  phenotype_term:
    preferred_term: Dolichocephaly
    term:
      id: HP:0000268
      label: Dolichocephaly
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The head shape is often described as long and narrow"
    explanation: GeneReviews' "often" wording supports the frequent band.
- name: Adipose tissue loss
  category: Growth
  description: >-
    Subcutaneous adipose tissue is sparse through childhood and adolescence,
    while central adiposity can emerge in adulthood.
  phenotype_term:
    preferred_term: Adipose tissue loss
    term:
      id: HP:0008887
      label: Adipose tissue loss
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subcutaneous adipose tissue is sparse throughout childhood and adolescence, but adults may develop central obesity."
    explanation: GeneReviews directly describes the age-dependent adipose phenotype without supplying a frequency band.
- name: Cutaneous photosensitivity
  category: Dermatologic
  frequency: VERY_FREQUENT
  description: >-
    A sun-sensitive, usually telangiectatic facial rash commonly emerges after
    sun exposure in the first or second year of life, with variable severity.
  phenotype_term:
    preferred_term: Cutaneous photosensitivity
    term:
      id: HP:0000992
      label: Cutaneous photosensitivity
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "typically following sun exposure during the first or second year of life, a red, sun-sensitive rash appears on the nose and cheeks"
    explanation: GeneReviews' "typically" wording supports the very-frequent band and characteristic early timing.
- name: Telangiectasia
  category: Dermatologic
  frequency: VERY_FREQUENT
  description: >-
    The characteristic sun-sensitive rash is usually telangiectatic, although
    poikilodermatous morphology can occur.
  phenotype_term:
    preferred_term: Telangiectasia
    term:
      id: HP:0001009
      label: Telangiectasia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is usually characterized by telangiectasia but in others is described as poikiloderma."
    explanation: GeneReviews' "usually" wording supports the very-frequent band.
- name: Hypogammaglobulinemia
  category: Immunologic
  frequency: VERY_FREQUENT
  description: >-
    One or more plasma immunoglobulin concentrations are usually low, most often
    IgM and IgA, within a broader variable adaptive immune phenotype.
  phenotype_term:
    preferred_term: Hypogammaglobulinemia
    term:
      id: HP:0004313
      label: Decreased circulating immunoglobulin concentration
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the concentration of one or more of the plasma immunoglobulins is usually abnormally low. IgM and IgA levels are most commonly affected."
    explanation: GeneReviews' "usually" wording supports the very-frequent band and identifies the commonly affected isotypes.
- name: Recurrent infections
  category: Immunologic
  description: >-
    Children experience more infections than unaffected peers, although
    opportunistic infection is not characteristic and severe invasive infection
    is uncommon.
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Parents of children with BSyn report that their affected children have more childhood infections than their sibs and peers"
    explanation: GeneReviews supports increased childhood infection frequency.
- name: Insulin resistance
  category: Endocrine
  description: >-
    Insulin resistance can begin in childhood and precedes the early-onset
    diabetes phenotype.
  phenotype_term:
    preferred_term: Insulin resistance
    term:
      id: HP:0000855
      label: Insulin resistance
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, and a high risk for many cancers that occur at an early age."
    explanation: GeneReviews lists insulin resistance among the defining clinical features.
- name: Diabetes mellitus
  category: Endocrine
  frequency: OCCASIONAL
  description: >-
    Diabetes resembles type 2 diabetes mechanistically but occurs much earlier
    and often despite low body mass index.
  phenotype_term:
    preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diabetes has been diagnosed in 51 of 294 persons in the Bloom Syndrome Registry (17.3%) at a mean age of 26.2 years (range: 4-48 years)."
    explanation: The registry frequency supports an occasional classification and early onset.
- name: Neoplasm
  category: Oncology
  frequency: VERY_FREQUENT
  description: >-
    Hematologic and solid malignancies arise early, and multiple primary cancers
    are common among affected people.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:35420546
    reference_title: "Age of first cancer diagnosis and survival in Bloom syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cumulative incidence of any malignancy by age 40 was 83%."
    explanation: Registry follow-up supports a very frequent, age-dependent cancer phenotype.
- name: Male infertility
  category: Reproductive
  frequency: VERY_FREQUENT
  description: >-
    Most evaluated males have azoospermia or severe oligospermia; confirmed
    paternity is exceptional.
  phenotype_term:
    preferred_term: Male infertility
    term:
      id: HP:0003251
      label: Male infertility
  phenotype_contexts:
  - sex: MALE
    notes: Applies to affected males assessed for infertility.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Most men with BSyn assessed for infertility have had azoospermia or severe oligospermia."
      explanation: GeneReviews directly describes the male-limited phenotype.
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "men tend to be infertile, with only one confirmed case of paternity."
    explanation: The summary supports male infertility as a characteristic feature.
- name: Premature ovarian insufficiency
  category: Reproductive
  frequency: FREQUENT
  description: >-
    Affected women can be fertile but commonly experience premature menopause.
  phenotype_term:
    preferred_term: Premature ovarian insufficiency
    term:
      id: HP:0008209
      label: Premature ovarian insufficiency
  phenotype_contexts:
  - sex: FEMALE
    notes: Applies to affected women; fertility can be preserved before early menopause.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Women with BSyn, although often fertile, may enter menopause prematurely."
      explanation: GeneReviews distinguishes preserved fertility from early ovarian failure.
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Women may be fertile but often have early menopause"
    explanation: The clinical summary supports premature ovarian insufficiency.
- name: Bronchiectasis
  category: Respiratory
  frequency: FREQUENT
  description: >-
    Chronic bronchitis and bronchiectasis are common; progressive pulmonary
    failure can be fatal.
  phenotype_term:
    preferred_term: Bronchiectasis
    term:
      id: HP:0002110
      label: Bronchiectasis
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic bronchitis and bronchiectasis are common, and pulmonary failure has been the cause of death in six persons."
    explanation: GeneReviews directly supports the pulmonary phenotype and severity.
- name: Hypothyroidism
  category: Endocrine
  description: >-
    Hypothyroidism can occur at an unusually early age and is monitored from
    childhood.
  phenotype_term:
    preferred_term: Hypothyroidism
    term:
      id: HP:0000821
      label: Hypothyroidism
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serious medical complications that are more common than in the general population and that also appear at unusually early ages include cancer of a wide variety of types and anatomic sites, diabetes mellitus as a result of insulin resistance, chronic obstructive pulmonary disease, and hypothyroidism."
    explanation: GeneReviews identifies hypothyroidism among complications that occur at unusually early ages.
genetic:
- name: BLM
  association: Biallelic loss-of-function
  gene_term:
    preferred_term: BLM
    term:
      id: hgnc:1058
      label: BLM
  notes: >-
    Pathogenic variants on both alleles establish Bloom syndrome. The common
    blmAsh founder allele is enriched in people of Eastern European Jewish
    ancestry, but this founder effect does not narrow the global disease
    definition.
  evidence:
  - reference: PMID:7585968
    reference_title: "The Bloom's syndrome gene product is homologous to RecQ helicases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presence of chain-terminating mutations in the candidate gene in persons with BS proved that it was BLM."
    explanation: >-
      The gene-discovery study established causal BLM loss-of-function variants
      in affected individuals.
  - reference: CGGV:assertion_e0a20b67-5a62-462c-894b-76b60a66e979-2019-04-19T160000.000Z
    reference_title: "BLM / Bloom syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "BLM | HGNC:1058 | Bloom syndrome | MONDO:0008876 | AR | Definitive"
    explanation: ClinGen classifies the BLM-Bloom syndrome gene-disease relationship as definitive with autosomal recessive inheritance.
  - reference: PMID:28232778
    reference_title: "Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A common founder mutation designated blmAsh is present in about 1 in 100 persons of Eastern European Jewish ancestry, and there are additional recurrent founder mutations among other populations."
    explanation: The review reports the ancestry-associated blmAsh founder allele while noting other population-specific founders.
diagnosis:
- name: BLM molecular genetic testing
  description: >-
    A compatible clinical presentation is confirmed by identifying biallelic
    pathogenic or likely pathogenic BLM variants. Sequence analysis should be
    complemented by deletion/duplication analysis when only one or no causal
    variant is found.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of BSyn is established in a proband with characteristic clinical features and biallelic pathogenic variants in BLM identified by molecular genetic testing."
    explanation: Current GeneReviews makes biallelic pathogenic BLM variants the diagnostic standard.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "If only one or no variant is detected by the sequencing method used"
    explanation: GeneReviews defines when sequence analysis should be followed by another method.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "to detect exon and whole-gene deletions or duplications."
    explanation: GeneReviews specifies the variants sought by follow-up deletion/duplication analysis.
- name: Sister-chromatid-exchange analysis
  description: >-
    Specialized cytogenetic analysis can show the highly elevated
    sister-chromatid-exchange signature and is useful when molecular testing is
    inconclusive. It is adjunctive, not independently diagnostic, because
    RMI1-, RMI2-, and TOP3A-related disorders can also increase SCEs.
  diagnosis_term:
    preferred_term: cytogenetic analysis
    term:
      id: NCIT:C18280
      label: Cytogenetic Analysis
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Increased frequency of SCEs is demonstrable in BSyn cultured cells (including lymphocytes, fibroblasts, and amniocytes) allowed to proliferate in a medium containing 5-bromo-2'-deoxyuridine (BrdU)."
    explanation: GeneReviews documents the characteristic SCE finding in cultured patient cells.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SCE analysis may be a useful adjunct for diagnosis of BSyn"
    explanation: GeneReviews explicitly positions SCE analysis as an adjunctive test.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Increased SCEs are not unique to BSyn."
    explanation: GeneReviews states the cellular finding is not specific to Bloom syndrome.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The presence of increased SCEs alone, however, is not sufficient to confirm the diagnosis of BSyn."
    explanation: GeneReviews directly limits the diagnostic interpretation of increased SCEs.
environmental:
- name: Ultraviolet radiation exposure
  description: >-
    Sunlight is the provoking exposure for the characteristic facial
    erythematous, telangiectatic eruption. Skin is generally unaffected at
    birth and the rash appears after the first sun exposures of infancy or
    early childhood, so photoprotection is a standing management
    recommendation and sun exposure is listed among the circumstances to
    avoid.
  exposure_term:
    preferred_term: exposure to ultraviolet radiation
    term:
      id: ECTO:0000006
      label: exposure to ultraviolet radiation
  exposure_classifications:
    hazard_agent_type:
    - classification_value: PHYSICAL
    exposure_route:
    - classification_value: DERMAL
      notes: >-
        Recorded as dermal because both the sun-sensitive eruption and the
        photoprotection recommendation concern skin exposed to sunlight.
    exposure_duration:
    - classification_value: LIFETIME
    exposome_domain:
    - classification_value: GENERAL_EXTERNAL
  influences_mechanisms:
  - target: Cutaneous photosensitivity
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Sun exposure is the proximate provocation for the sun-sensitive facial
      rash rather than a background aggravating factor, because the skin is
      generally normal until the first exposures occur.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
      reference_title: Bloom Syndrome - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "typically following sun exposure during the first or second year of life, a red, sun-sensitive rash appears on the nose and cheeks"
      explanation: GeneReviews ties first appearance of the eruption to the first sun exposures, which supports ultraviolet light as the trigger for this phenotype.
  evidence:
  - reference: PMID:20301572
    reference_title: Bloom Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Sun exposure to the face and other exposed skin, particularly in infancy and early childhood, should be avoided."
    explanation: GeneReviews lists sun exposure among the agents and circumstances to avoid, which treats it as a modifiable exposure in this disease rather than an incidental one.
  review_notes: >-
    Scoped to the sun-sensitive eruption, which is the manifestation the
    sources tie directly to sun exposure. No claim is made here that
    ultraviolet exposure measurably drives the overall cancer burden in Bloom
    syndrome; the registry cancer spectrum is dominated by hematologic and
    gastrointestinal tumours rather than by skin cancers.
- name: Ionizing radiation exposure
  description: >-
    Diagnostic and therapeutic ionizing radiation is treated as a modifiable
    exposure. BLM-deficient cells resolve radiation-induced DNA damage poorly,
    guidance is to minimize radiation exposure and prefer non-ionizing imaging
    for surveillance, and radiotherapy is avoided when a clinically acceptable
    alternative exists. Evidence that radiotherapy actually causes second
    cancers in Bloom syndrome remains indirect.
  exposure_term:
    preferred_term: exposure to ionizing radiation
    term:
      id: ECTO:7000047
      label: exposure to ionizing radiation
  exposure_classifications:
    hazard_agent_type:
    - classification_value: PHYSICAL
    exposure_route:
    - classification_value: MULTIPLE
      notes: >-
        External irradiation is not absorbed by a single portal of entry, so
        MULTIPLE is recorded rather than a chemical-style route.
    exposure_duration:
    - classification_value: INTERMITTENT
      notes: >-
        The relevant exposures are discrete medical events, principally
        diagnostic imaging and therapeutic radiotherapy.
    exposome_domain:
    - classification_value: SPECIFIC_EXTERNAL
  influences_mechanisms:
  - target: Early-Onset Multicancer Predisposition
    environmental_effect: EXACERBATES
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Radiation-induced double-strand breaks add lesions to a genome that
      already mis-resolves recombination intermediates without BLM, so the
      exposure adds to an existing predisposition rather than initiating it.
      EXACERBATES rather than TRIGGERS because the biallelic BLM lesion is
      what establishes the cancer predisposition.
    evidence:
    - reference: PMID:38995367
      reference_title: Rare case of myelodysplastic syndrome with excess blasts 2 developing after adjuvant chemoradiotherapy for triple-negative breast cancer in a patient with Bloom syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Irradiated Blm-deficient mice (Blmm3/m3) exhibited an increased risk for tumors, particularly hematological malignancies"
      explanation: An irradiated Blm-deficient mouse model shows radiation raising tumour risk on a BLM-deficient background, which is the mechanism this edge asserts. Model-organism evidence, so it does not by itself establish the effect in patients.
  evidence:
  - reference: PMID:20301572
    reference_title: Bloom Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Exposure to ionizing radiation should be minimized."
    explanation: GeneReviews lists minimizing ionizing radiation among the agents and circumstances to avoid, which is the management consequence of treating it as a risk factor.
  - reference: PMID:38995367
    reference_title: Rare case of myelodysplastic syndrome with excess blasts 2 developing after adjuvant chemoradiotherapy for triple-negative breast cancer in a patient with Bloom syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with BS, significant sensitivity to both DNA-damaging chemotherapy (CT) and ionizing radiation complicates the management of neoplasms by exacerbating comorbidities and predisposing to toxicities and poor outcomes."
    explanation: States the clinical premise for treating ionizing radiation as a hazardous exposure in this disease.
  - reference: PMID:40641635
    reference_title: Management of Paediatric Cancers Associated With Bloom Syndrome.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Interestingly, radiotherapy was well tolerated, with no complications in the two patients treated, challenging previous assumptions about its risk in BS"
    explanation: The largest paediatric series to date found radiotherapy acutely well tolerated, which cuts against a blanket radiation-hazard claim. Two patients cannot establish safety, but the observation is recorded rather than dropped because it is the only direct paediatric evidence on tolerability.
  review_notes: >-
    The supporting human evidence is about hypersensitivity and treatment
    toxicity, not about a measured excess of radiation-induced cancers in
    Bloom syndrome; the carcinogenicity half of the claim rests on the mouse
    model and on single case reports. No IARC group is recorded here because
    the entry describes medical radiation exposure in this disease rather
    than an agent-level carcinogen assessment.
- name: DNA-damaging antineoplastic agent exposure
  description: >-
    Cytotoxic chemotherapy, and alkylating agents in particular, are the
    iatrogenic exposure of greatest concern once a Bloom syndrome patient
    develops cancer. Clinicians report severe toxicity at conventional doses
    and recommend avoiding alkylators, topoisomerase inhibitors, and
    anthracyclines where the disease allows.
  exposure_term:
    preferred_term: exposure to antineoplastic agent
    term:
      id: ECTO:9001737
      label: exposure to antineoplastic agent
  exposure_classifications:
    hazard_agent_type:
    - classification_value: CHEMICAL
    exposure_route:
    - classification_value: PARENTERAL
    exposure_duration:
    - classification_value: INTERMITTENT
    exposome_domain:
    - classification_value: SPECIFIC_EXTERNAL
  influences_mechanisms:
  - target: Early-Onset Multicancer Predisposition
    environmental_effect: EXACERBATES
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      DNA-damaging cytotoxics are given against a first cancer and add
      genomic lesions to cells that already mis-resolve recombination
      intermediates, which is the stated reason for avoiding alkylating
      agents in this population. Registry acute myeloid leukaemias in Bloom
      syndrome followed chemotherapy for a prior tumour.
    evidence:
    - reference: PMID:38995367
      reference_title: Rare case of myelodysplastic syndrome with excess blasts 2 developing after adjuvant chemoradiotherapy for triple-negative breast cancer in a patient with Bloom syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Although there are no evidence-based data linking specific chemotherapeutic agents to an increased risk of secondary malignancies, most treating clinicians recommend against the use of alkylating agents, particularly busulfan, cyclophosphamide, or melphalan, due to their direct interaction with DNA."
      explanation: Records both the practice recommendation and, in the same sentence, that it rests on mechanism and clinical judgement rather than on comparative outcome data.
  evidence:
  - reference: PMID:33226170
    reference_title: Multidisciplinary management of endocrinopathies and treatment-related toxicities in patients with Bloom syndrome and cancer.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "we recommend avoidance of the use of alkylating agents, topoisomerases and anthracyclines due to the risks of secondary malignancy and cardiotoxicity."
    explanation: Names the specific drug classes treated as hazardous exposures in Bloom syndrome and the harms they are avoided for.
  - reference: PMID:40641635
    reference_title: Management of Paediatric Cancers Associated With Bloom Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Treating cancer in BS patients is challenging due to heightened sensitivity to DNA-damaging therapies, including alkylating agents and radiotherapy"
    explanation: A national multicentre series states the heightened sensitivity to DNA-damaging therapy that makes this an exposure to manage rather than an ordinary treatment choice.
  review_notes: >-
    Curated as an iatrogenic exposure because the sources treat it as one, not
    to imply that chemotherapy should be withheld: the same paediatric series
    reports remissions in patients who received dose-reduced regimens. See the
    reduced-toxicity cancer therapy treatment for the management side.
treatments:
- name: Nutritional, feeding, and reflux management
  description: >-
    Use calorie-dense formulas or foods when appropriate, involve
    gastroenterology or feeding specialists, and treat gastroesophageal reflux
    as needed.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  - preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Increased-calorie-density formulas and foods may promote weight gain; consultation with gastroenterologist or feeding specialist and treatment for gastroesophageal reflux disease as needed; standard dietary treatment for dyslipidemia."
    explanation: GeneReviews provides supportive nutritional, feeding-specialist, and reflux-management guidance.
- name: Rigorous sun protection
  description: >-
    Avoid excessive ultraviolet exposure, use sun-protective clothing and a
    broad-brimmed hat, wear UV-blocking sunglasses, and apply broad-spectrum
    sunscreen with SPF 30 or higher.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Cutaneous photosensitivity
    term:
      id: HP:0000992
      label: Cutaneous photosensitivity
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Skin protection, including avoiding excessive sun exposure, sun-protective clothing and broad-brimmed hat, UV-blocking sunglasses, and use of broad-spectrum sunscreen with SPF of at least 30"
    explanation: GeneReviews specifies a practical ultraviolet-protection regimen.
  target_mechanisms:
  - target: Cutaneous photosensitivity
    treatment_effect: MODULATES
    description: Reducing ultraviolet exposure decreases provocation and severity of the sun-sensitive rash.
    evidence:
    - reference: PMID:20301572
      reference_title: "Bloom Syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Skin protection, including avoiding excessive sun exposure"
      explanation: Avoidance directly reduces the environmental trigger for the phenotype.
- name: Immunoglobulin replacement for selected patients
  description: >-
    Individuals with recurrent infections and documented humoral immune defects
    may receive immunoglobulin replacement to reduce infection frequency and
    severity; this is not a universal treatment for every affected person.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: intravenous immunoglobulin therapy
    term:
      id: NCIT:C62710
      label: Immunoglobulin Therapy
  target_phenotypes:
  - preferred_term: Hypogammaglobulinemia
    term:
      id: HP:0004313
      label: Decreased circulating immunoglobulin concentration
  - preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Individuals with recurrent infections and defects in humoral immunity may be treated with immunoglobulins to decrease frequency and severity of infections."
    explanation: GeneReviews bounds replacement therapy to clinically and immunologically selected patients.
  target_mechanisms:
  - target: Hypogammaglobulinemia
    treatment_effect: RESTORES
    description: Exogenous immunoglobulin replaces deficient circulating antibody function.
    evidence:
    - reference: PMID:20301572
      reference_title: "Bloom Syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "may be treated with immunoglobulins to decrease frequency and severity of infections."
      explanation: The clinical recommendation supports functional antibody replacement.
- name: Age- and organ-specific cancer surveillance
  description: >-
    Intensive surveillance includes Wilms-tumor abdominal ultrasound in early
    childhood, leukemia/lymphoma symptom review, non-ionizing whole-body MRI
    from adolescence, early colorectal screening, and early breast MRI. The
    schedule should follow current predisposition guidance and specialist care.
  action_category: SCREENING
  treatment_term:
    preferred_term: cancer screening
    term:
      id: NCIT:C15406
      label: Cancer Screening
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Clinical assessment for hematuria and/or abdominal mass and abdominal ultrasound examination every three months until age eight years for Wilms tumor."
    explanation: GeneReviews provides a concrete early-childhood component of surveillance.
  - reference: PMID:39264246
    reference_title: "Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Recognition of children with genomic instability disorders is important in order to make the proper diagnosis, enable genetic counseling, and inform cancer screening, cancer risk reduction, and choice of anticancer therapy."
    explanation: The AACR guideline explicitly includes Bloom syndrome in genomic-instability surveillance.
  - reference: PMID:20301572
    reference_title: Bloom Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Skin exam with a dermatologist upon recognition of suspicious skin lesions and annually thereafter."
    explanation: Adds the dermatologic component of surveillance, which is the organ-specific counterpart to the ultraviolet exposure recorded as a risk factor.
  review_notes: >-
    Surveillance recommendations are expert consensus informed by registry
    experience; they have not been validated in randomized or case-control
    outcome studies in Bloom syndrome.
- name: Individualized reduced-toxicity cancer therapy
  description: >-
    Cancer treatment is individualized by oncology specialists, commonly with
    reduced dosage or duration because standard regimens can cause excessive
    toxicity. Ionizing radiation and alkylating agents are minimized or avoided
    when clinically feasible; undertreatment is also a risk, so no universal
    dose reduction is asserted.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In persons with cancer, modification of chemotherapy dosage and duration per oncologist."
    explanation: GeneReviews recommends individualized oncologist-directed modification.
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Alkylating agents and radiation therapy are considered high risk and are avoided when possible in those with BSyn."
    explanation: The source supports minimizing particularly hazardous modalities.
  - reference: PMID:33226170
    reference_title: Multidisciplinary management of endocrinopathies and treatment-related toxicities in patients with Bloom syndrome and cancer.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We recommend starting at lower doses and escalating as tolerated, with close monitoring for toxicity as further dose modifications may be required in order to complete therapy."
    explanation: Gives the dosing strategy behind individualized reduced-toxicity therapy, namely starting low, escalating to tolerance, and expecting further modification.
  - reference: PMID:33226170
    reference_title: Multidisciplinary management of endocrinopathies and treatment-related toxicities in patients with Bloom syndrome and cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally, significant dose reductions ranging from 20-60% of typical dosing of many of the other chemotherapeutic agents allowed for tolerable toxicities in our patients throughout treatment with remission induction in our patient with AML and long-term remission in our patient with ALL."
    explanation: Two patients treated at 20 to 60 percent of standard doses tolerated therapy and entered remission, which is the outcome evidence that dose reduction need not mean undertreatment. Two cases, so the range is a reported experience rather than a validated schedule.
  - reference: PMID:40641635
    reference_title: Management of Paediatric Cancers Associated With Bloom Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is noteworthy that all patients who achieved remission had undergone dose reductions in chemotherapy, tailored to individual tolerance."
    explanation: In the largest paediatric series, every remission occurred under individually tailored dose reduction, supporting individualization rather than a fixed protocol.
  - reference: PMID:40641635
    reference_title: Management of Paediatric Cancers Associated With Bloom Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, five achieved remission, highlighting the possibility of curative treatment despite significant toxicities."
    explanation: Establishes that curative intent remains achievable, which is the counterweight to reflexive undertreatment.
  review_notes: >-
    No universal dose reduction is asserted. The quantitative reductions cited
    come from two case reports and a nine-patient retrospective series, and
    the same paediatric series records one treatment-related death, so the
    evidence supports individualization and close monitoring rather than any
    specific percentage.
- name: Metabolic and thyroid surveillance
  description: >-
    Beginning in childhood, annual fasting glucose, hemoglobin A1c, and thyroid
    testing support early detection and standard treatment of diabetes and
    hypothyroidism.
  action_category: MONITORING
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Annual fasting blood glucose and hemoglobin A1c beginning at age ten years. Annual serum TSH with reflex to thyroxine beginning at age ten years."
    explanation: GeneReviews specifies annual metabolic and thyroid surveillance from age ten.
- name: Airway-clearance and pulmonary care
  description: >-
    Recurrent or chronic pulmonary disease is assessed at each visit.
    Bronchiectasis care can include cough-assist devices, vibration vests, and
    daily nasal lavage for mucociliary clearance.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Bronchiectasis
    term:
      id: HP:0002110
      label: Bronchiectasis
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cough assist devices, vibration vests, and daily nasal lavage for mucociliary clearance for bronchiectasis."
    explanation: GeneReviews lists the airway-clearance measures used for bronchiectasis.
- name: Hematopoietic cell transplantation for hematologic malignancy
  description: >-
    Allogeneic transplantation is used for hematologic malignancy in Bloom
    syndrome, but the reported experience is small and toxicity is
    substantial, because conditioning regimens deliver exactly the
    DNA-damaging exposure these patients tolerate poorly. It is a
    specialist-directed option under active uncertainty rather than a
    standard-of-care recommendation.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_phenotypes:
  - preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:40641635
    reference_title: Management of Paediatric Cancers Associated With Bloom Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There is limited literature about HSCT and BS for children"
    explanation: Establishes that transplantation is used in this population while the evidence base for it is acknowledged as thin.
  - reference: PMID:40641635
    reference_title: Management of Paediatric Cancers Associated With Bloom Syndrome.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "In our experience, one patient underwent HSCT with a myeloablative conditioning regimen but died shortly after transplantation due to treatment-related toxicity, despite being in remission at the time."
    explanation: A myeloablative transplant in remission ended in treatment-related death, which cuts against transplantation with full-intensity conditioning as a safe option here. One patient, so it bounds enthusiasm rather than establishing a rule.
  review_notes: >-
    Recorded because transplantation is performed in this disease and the
    outcome data belong in the entry, not because the evidence supports
    recommending it. The single detailed paediatric case used myeloablative
    conditioning and died of toxicity; no Bloom syndrome series comparing
    reduced-intensity with myeloablative conditioning was found, so no
    conditioning-intensity recommendation is asserted.
- name: Multidisciplinary endocrine and metabolic co-management during cancer therapy
  description: >-
    The endocrinopathies that are already characteristic of Bloom syndrome,
    principally insulin-resistant diabetes, dyslipidemia, and hypothyroidism,
    are destabilized by cancer treatment, and steroid and asparaginase
    exposure add adrenal insufficiency and severe hypertriglyceridemia. Joint
    oncology and endocrinology management is recommended for the duration of
    therapy.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  - preferred_term: Hypothyroidism
    term:
      id: HP:0000821
      label: Hypothyroidism
  evidence:
  - reference: PMID:33226170
    reference_title: Multidisciplinary management of endocrinopathies and treatment-related toxicities in patients with Bloom syndrome and cancer.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A multidisciplinary team of oncologists and endocrinologists is best suited to care for this patient population."
    explanation: States the co-management recommendation this treatment records.
  - reference: PMID:33226170
    reference_title: Multidisciplinary management of endocrinopathies and treatment-related toxicities in patients with Bloom syndrome and cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both patients experienced severe toxicities and exacerbation of endocrine comorbidities during chemotherapy."
    explanation: Supplies the observation that motivates co-management, namely that pre-existing endocrine disease worsened under treatment in both reported patients.
- name: Genetic counseling and reproductive options
  description: >-
    Bloom syndrome is autosomal recessive, so each subsequent sibling has a
    one-in-four recurrence risk. Once both familial BLM variants are known,
    prenatal and preimplantation genetic testing are available, and carrier
    screening panels commonly include the condition. Evaluating at-risk
    siblings also allows sun avoidance and cancer surveillance to start early.
  action_category: COUNSELING_INFORMATIONAL
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301572
    reference_title: Bloom Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Once the BLM pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing are possible."
    explanation: Establishes the reproductive testing options this counseling action conveys.
  - reference: PMID:20301572
    reference_title: Bloom Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It is appropriate to evaluate sibs of a proband in order to identify as early as possible those who would benefit from avoidance of sun exposure and early surveillance for cancer."
    explanation: Supports sibling evaluation as an actionable counseling step, and links it to the two interventions this entry records as effective.
- name: Developmental and educational support
  description: >-
    Developmental services and educational support are provided as needed.
    Intellectual ability is usually normal in Bloom syndrome, so this is
    individualized support rather than a universal expectation of
    developmental delay.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301572
    reference_title: Bloom Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Developmental services and educational support as needed."
    explanation: GeneReviews lists developmental and educational support among the management measures, qualified as needed.
differential_diagnoses:
- name: Fanconi anemia
  disease_term:
    preferred_term: Fanconi anemia
    term:
      id: MONDO:0019391
      label: Fanconi anemia
  description: >-
    Fanconi anemia overlaps with Bloom syndrome through chromosome instability,
    cancer predisposition, pigmentary change, growth deficiency, and reduced
    fertility. Skeletal malformations and progressive bone-marrow failure favor
    Fanconi anemia.
  distinguishing_features:
  - Markedly elevated sister-chromatid exchange favors Bloom syndrome.
  - Bone marrow failure and congenital radial-ray anomalies favor Fanconi anemia.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Bone marrow failure"
    explanation: The GeneReviews differential table identifies bone-marrow failure as a key feature favoring Fanconi anemia.
- name: Nijmegen breakage syndrome
  disease_term:
    preferred_term: Nijmegen breakage syndrome
    term:
      id: MONDO:0009623
      label: Nijmegen breakage syndrome
  description: >-
    Nijmegen breakage syndrome is another DNA-repair disorder with
    growth deficiency, genomic instability, immunodeficiency, and lymphoid
    cancer predisposition. Declining intellectual performance and absence of
    telangiectasias distinguish it from the usual Bloom presentation.
  distinguishing_features:
  - Elevated sister-chromatid exchange and a sun-sensitive malar rash favor Bloom syndrome.
  - Declining intellectual performance and lymphoid-predominant malignancy favor Nijmegen breakage syndrome.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Decline in intellectual performance"
    explanation: GeneReviews identifies declining intellectual performance as a feature favoring Nijmegen breakage syndrome.
- name: Rothmund-Thomson syndrome
  disease_term:
    preferred_term: Rothmund-Thomson syndrome
    term:
      id: MONDO:0010002
      label: Rothmund-Thomson syndrome
  description: >-
    RECQL4-related Rothmund-Thomson syndrome overlaps through small stature and
    cancer susceptibility, but true poikiloderma, alopecia, juvenile cataracts,
    and premature-aging features favor that diagnosis.
  distinguishing_features:
  - A sun-sensitive facial rash and highly elevated sister-chromatid exchange favor Bloom syndrome.
  - True poikiloderma, juvenile cataracts, and premature aging favor Rothmund-Thomson syndrome.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "True poikiloderma (not sun-sensitive rash)"
    explanation: GeneReviews distinguishes true poikiloderma in RECQL4 disease from the Bloom sun-sensitive rash.
clinical_trials:
- name: NCT00021437
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Historical observational Bloom Syndrome Registry and laboratory protocol
    following affected families, documenting cancers and studying chromosomes
    and mutations in blood or skin-derived cells. It is not an interventional
    efficacy trial and does not represent a current disease-modifying therapy.
  evidence:
  - reference: clinicaltrials:NCT00021437
    reference_title: "Biological Significance of the Bloom's Syndrome Protein"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We are defining the clinical syndrome and at the same time are studying cells from affected families in the experimental laboratory."
    explanation: The official record describes combined registry observation and laboratory investigation.
  notes: >-
    ClinicalTrials.gov listed the study as completed and observational when
    checked on 2026-07-23. Other search results using BLOOM as an acronym were
    unrelated to Bloom syndrome and were excluded.
animal_models:
- species: Mus musculus
  genotype: Blm-deficient Bloom mouse
  genes:
  - preferred_term: Blm
    term:
      id: MGI:107573
      label: Blm
  description: >-
    Viable Blm-deficient mice develop diverse cancers and show increased
    mitotic recombination and loss of heterozygosity. The model supplies in-vivo
    causal evidence for the cancer branch but does not establish mechanisms for
    human growth, immune, dermatologic, or endocrine manifestations.
  associated_phenotypes:
  - Diverse malignancies
  - Increased mitotic recombination
  - Loss of heterozygosity
  evidence:
  - reference: PMID:11101838
    reference_title: "Cancer predisposition caused by elevated mitotic recombination in Bloom mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Using embryonic stem cell technology, we have generated viable Bloom mice that are prone to a wide variety of cancers."
    explanation: The primary model paper establishes viability and broad cancer predisposition.
  - reference: PMID:11101838
    reference_title: "Cancer predisposition caused by elevated mitotic recombination in Bloom mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Cell lines from these mice show elevations in the rates of mitotic recombination."
    explanation: The model reproduces the central cellular recombination phenotype.
datasets:
- accession: geo:GSE283485
  title: G-quadruplexes regulate chromatin accessibility and gene expression in Bloom Syndrome [RNA-seq]
  description: >-
    Public RNA-seq series containing 24 samples from BLM-deficient and
    wild-type lymphoblastoid and fibroblast cell lines, with wild-type
    pyridostatin and vehicle perturbations. The associated preprint also reports
    ATAC-seq and G4 ChIP-seq; the data support an emerging regulatory hypothesis
    rather than a validated explanation for the clinical syndrome.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 24
  conditions:
  - BLM-deficient lymphoblastoid cell lines
  - Wild-type lymphoblastoid cell lines
  - BLM-deficient fibroblast cell lines
  - Wild-type fibroblast cell lines
  - Pyridostatin-treated wild-type cells
  - Vehicle-treated wild-type cells
  genes:
  - preferred_term: BLM
    term:
      id: hgnc:1058
      label: BLM
  publication: PMID:41867784
  evidence:
  - reference: PMID:41867784
    reference_title: "G-quadruplexes regulate chromatin accessibility and gene expression in Bloom Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here, we profiled chromatin accessibility and gene expression using ATAC-seq and RNA-seq and mapped endogenous G4 by ChIP-seq in wild type (WT) and BS cell lines."
    explanation: The associated preprint describes the molecular profiling represented by the public series.
discussions:
- discussion_id: bloom_nonmalignant_mechanism_gap
  prompt: >-
    Which molecular consequences of BLM loss cause growth restriction, sparse
    adipose tissue, feeding difficulty and reflux, the narrow facial gestalt,
    photosensitivity and telangiectasia, immune abnormalities, insulin
    resistance, infertility, bronchiectasis, and hypothyroidism?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Unresolved Nonmalignant Multisystem Consequences
  rationale: >-
    The chromosome-instability-to-cancer branch is experimentally supported,
    but assigning that same route to every nonmalignant phenotype would exceed
    current evidence.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
    reference_title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "remains unexplained, as do the medical complications of BSyn other than cancer."
    explanation: GeneReviews explicitly states the central mechanistic gap.
- discussion_id: bloom_surveillance_outcome_gap
  prompt: >-
    How much do individual components of intensive cancer surveillance improve
    stage at diagnosis, treatment burden, and survival in Bloom syndrome?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Neoplasm
  - treatments#Age- and organ-specific cancer surveillance
  rationale: >-
    Current schedules are clinically important consensus guidance, but the
    disease is exceptionally rare and component-specific outcome evidence is
    limited.
  evidence:
  - reference: PMID:30055079
    reference_title: "Health supervision for people with Bloom syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The purpose of this report is to use information from the BSyn Registry, published literature, and expertise from clinicians and researchers with experience in BSyn to develop recommendations for diagnosis, screening, and treatment"
    explanation: The consensus paper states the evidence basis for surveillance recommendations.
- discussion_id: bloom_g4_regulatory_hypothesis
  prompt: >-
    Do unresolved G-quadruplexes and altered chromatin accessibility materially
    contribute to human Bloom syndrome manifestations beyond the established
    hyper-recombination pathway?
  kind: EMERGING_HYPOTHESIS
  status: OPEN
  attaches_to:
  - pathophysiology#Biallelic BLM Loss of Function
  rationale: >-
    A 2026 preprint reports correlated G4, accessibility, and expression
    changes in cell lines, plus partial phenocopy after G4 stabilization. It is
    promising but not yet sufficient for promotion into the core clinical
    mechanism graph.
  evidence:
  - reference: PMID:41867784
    reference_title: "G-quadruplexes regulate chromatin accessibility and gene expression in Bloom Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "G4 stabilization partially recapitulated BS-associated molecular phenotypes."
    explanation: This perturbation result motivates the hypothesis while remaining preclinical and preprint evidence.
- discussion_id: bloom_heterozygote_cancer_risk
  prompt: >-
    Does heterozygous BLM carrier status materially increase cancer risk in
    defined populations or exposure contexts?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - genetic#BLM
  rationale: >-
    Bloom syndrome itself requires biallelic pathogenic variants. Carrier-risk
    claims should not be imported into the disease mechanism without
    population-specific evidence and replication.
  evidence:
  - reference: PMID:20301572
    reference_title: "Bloom Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Heterozygotes (carriers) are not at risk of developing BSyn; the cancer risk of heterozygotes as a group remains unclear."
    explanation: Current GeneReviews preserves the uncertainty while separating carriers from affected people.
references:
- reference: PMID:20301572
  title: "Bloom Syndrome."
  findings: []
  tags:
  - GeneReviews
- reference: PMID:35420546
  title: "Age of first cancer diagnosis and survival in Bloom syndrome."
  findings: []
- reference: CGGV:assertion_e0a20b67-5a62-462c-894b-76b60a66e979-2019-04-19T160000.000Z
  title: "BLM / Bloom syndrome (Definitive)"
  findings: []
- reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
  title: "Bloom Syndrome - GeneReviews® - NCBI Bookshelf"
  findings: []
- reference: PMID:7585968
  title: "The Bloom's syndrome gene product is homologous to RecQ helicases."
  findings: []
- reference: PMID:14685245
  title: "The Bloom's syndrome helicase suppresses crossing over during homologous recombination."
  findings: []
- reference: PMID:25794620
  title: "TopBP1 interacts with BLM to maintain genome stability but is dispensable for preventing BLM degradation."
  findings: []
- reference: PMID:28232778
  title: "Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition."
  findings: []
- reference: PMID:21730139
  title: "Interhomolog recombination and loss of heterozygosity in wild-type and Bloom syndrome helicase (BLM)-deficient mammalian cells."
  findings: []
- reference: PMID:11101838
  title: "Cancer predisposition caused by elevated mitotic recombination in Bloom mice."
  findings: []
- reference: PMID:39264246
  title: "Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders."
  findings: []
- reference: clinicaltrials:NCT00021437
  title: "Biological Significance of the Bloom's Syndrome Protein"
  findings: []
- reference: PMID:41867784
  title: "G-quadruplexes regulate chromatin accessibility and gene expression in Bloom Syndrome."
  findings: []
- reference: PMID:30055079
  title: "Health supervision for people with Bloom syndrome."
  findings: []
review_notes: >-
  Comprehensive re-review completed 2026-07-23. Scope is restricted to
  biallelic BLM-related Bloom syndrome; heterozygous carrier cancer-risk claims
  are not treated as disease manifestations. Sister-chromatid exchange is
  modeled as a positive cellular readout of mitotic hyper-recombination and a
  characteristic adjunctive cytogenetic finding, not a pathognomonic standalone
  diagnostic test, because RMI1-, RMI2-, and TOP3A-related disorders can also
  elevate SCEs. The atomic cancer chain is BTRR dissolution failure to mitotic
  hyper-recombination, increased loss of heterozygosity, and early multicancer
  predisposition. Growth, adipose, craniofacial, gastrointestinal, immune,
  dermatologic, metabolic, reproductive, pulmonary, and thyroid findings are
  deliberately connected through an unknown-intermediates node because
  GeneReviews states that these noncancer mechanisms remain unexplained. The D2P audit surfaced many
  source-candidate phenotypes, but only major features with exact
  disease-specific evidence were added. Registry percentages are kept within
  their ascertainment and age boundaries. Cancer surveillance recommendations
  are expert consensus informed by registry experience rather than proven
  component-specific outcome effects. NCT00021437 is a completed historical
  observational registry/laboratory protocol, not a therapeutic trial; unrelated
  BLOOM-acronym studies were excluded. GSE283485 and the associated 2026
  preprint are represented as an emerging G-quadruplex regulatory hypothesis,
  not as settled clinical mechanism. The earlier Asta research output was noisy,
  so final curation relied on direct review of primary PubMed records,
  GeneReviews, ClinGen, ClinicalTrials.gov, and the public dataset record.
  Treatment and risk-factor pass 2026-09-10. An environmental section was added
  covering the three exposures the sources treat as modifiable in this disease,
  namely ultraviolet radiation, ionizing radiation, and DNA-damaging
  antineoplastic agents. Only the ultraviolet edge is TRIGGERS and it is scoped
  to the sun-sensitive eruption, not to the cancer burden, which registry data
  show is dominated by hematologic and gastrointestinal tumours. The ionizing
  radiation and chemotherapy edges are EXACERBATES against the multicancer
  predisposition node, because the biallelic BLM lesion establishes the
  predisposition and the exposures add to it. Human evidence for those two
  concerns hypersensitivity and treatment toxicity rather than a measured
  excess of treatment-induced cancers, so the carcinogenicity half rests on an
  irradiated Blm-deficient mouse model and on case reports, and the largest
  paediatric series reporting radiotherapy acutely well tolerated in two
  children is carried as REFUTE evidence rather than dropped. Four treatments
  were added. Hematopoietic cell transplantation is recorded because it is
  performed, with the single detailed paediatric myeloablative case carried as
  REFUTE evidence; no conditioning-intensity recommendation is asserted because
  no Bloom syndrome comparison of reduced-intensity with myeloablative
  conditioning was found. Quantitative chemotherapy dose reductions are cited
  from two case reports and a nine-patient retrospective series, so they
  support individualization rather than any specific percentage. Growth hormone
  therapy was searched for and deliberately omitted, because no source in the
  cached set states a Bloom-syndrome-specific recommendation on it.
📚

References & Deep Research

References

14
PMID:20301572
Bloom Syndrome.
No top-level findings curated for this source.
PMID:35420546
Age of first cancer diagnosis and survival in Bloom syndrome.
No top-level findings curated for this source.
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/books/NBK1398/
Bloom Syndrome - GeneReviews® - NCBI Bookshelf
No top-level findings curated for this source.
PMID:7585968
The Bloom's syndrome gene product is homologous to RecQ helicases.
No top-level findings curated for this source.
PMID:14685245
The Bloom's syndrome helicase suppresses crossing over during homologous recombination.
No top-level findings curated for this source.
PMID:25794620
TopBP1 interacts with BLM to maintain genome stability but is dispensable for preventing BLM degradation.
No top-level findings curated for this source.
PMID:28232778
Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition.
No top-level findings curated for this source.
PMID:21730139
Interhomolog recombination and loss of heterozygosity in wild-type and Bloom syndrome helicase (BLM)-deficient mammalian cells.
No top-level findings curated for this source.
PMID:11101838
Cancer predisposition caused by elevated mitotic recombination in Bloom mice.
No top-level findings curated for this source.
PMID:39264246
Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders.
No top-level findings curated for this source.
clinicaltrials:NCT00021437
Biological Significance of the Bloom's Syndrome Protein
No top-level findings curated for this source.
PMID:41867784
G-quadruplexes regulate chromatin accessibility and gene expression in Bloom Syndrome.
No top-level findings curated for this source.
PMID:30055079
Health supervision for people with Bloom syndrome.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Asta ▸
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Bloom syndrome. Core disease mechanisms, molecular and cellular pathways,...
Asta Scientific Corpus Retrieval 20 citations 2026-04-11T15:59:58.783878

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Bloom syndrome. Core disease mechanisms, molecular and cellular pathways,...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 20
  • Snippets retrieved: 20

Relevant Papers

[1] 18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases

  • Authors: E. Nemutlu, Song Zhang, N. Juranic, A. Terzic, S. Macura et al.
  • Year: 2012
  • Venue: Croatian Medical Journal
  • URL: https://www.semanticscholar.org/paper/880f053c7f060db4b990e447d0a22c4b69372ddb
  • DOI: 10.3325/cmj.2012.53.529
  • PMID: 23275318
  • PMCID: 3541579
  • Citations: 28
  • Summary: The potential use of dynamic phosphometabolomic platform for disease diagnostics currently under development at Mayo Clinic is described and discussed briefly.
  • Evidence snippets:
  • Snippet 1 (score: 0.399) > Living cells represent an integrated and interacting network of genes, transcripts, proteins, small signaling molecules, and metabolites that define cellular phenotype and function. Traditionally the focus of biomedical research was on individual genes, single protein targets, single metabolites, and metabolic or signaling pathways. This "molecular reductionist" paradigm was based on the assumption that identifying genetic variations and molecular components would lead to discovery of cures for human diseases. However, most of diseases are complex and multi-factorial and the disease phenotype is determined by the alterations of multiple genes, pathways, proteins and metabolites (at cellular, tissue, and organismal levels). Therefore, an integrated "omics" approach is more viable direction for uncovering alterations in metabolic networks, disease mechanisms, and mechanisms of drug effects. > Recent advent of large-scale metabolomics and fluxomic (metabolite dynamics and metabolic flux analysis) completed the "omics revolution" (Figure 1), where genomics, transcriptomics, proteomics, metabolomics, and fluxomics all together complement phenotype determination of living organism. Such integrated "omics" cascades provide a framework for advances in system and network biology, integrative physiology, and system medicine as well as system pharmacology and regenerative medicine. Noteworthy is the "reverse omic" approach or "metabolomicsinformed pharmacogenomics, " where discovery of specific metabolite changes have led to discovery of genetic alterations (2). Therefore, bringing new "omics" technologies to clinical practice will improve disease diagnostics and treatment by targeting drugs and procedures for each unique transcriptomic and metabolomic profiles.

[2] Novel variants in KAT6B spectrum of disorders expand our knowledge of clinical manifestations and molecular mechanisms

  • Authors: M. Yabumoto, Jessica Kianmahd, Meghna Singh, Maria F. Palafox, Angela Wei et al.
  • Year: 2021
  • Venue: Molecular Genetics & Genomic Medicine
  • URL: https://www.semanticscholar.org/paper/3a47a1b1208ba7420900b090d3d7d712ed391719
  • DOI: 10.1002/mgg3.1809
  • PMID: 34519438
  • PMCID: 8580094
  • Citations: 12
  • Influential citations: 2
  • Summary: A range of features previously described for KAT6B‐related syndromes are identified, including concern for keratoconus, sensitivity to light or noise, recurring infections, and fractures in greater numbers than previously reported.
  • Evidence snippets:
  • Snippet 1 (score: 0.367) > Finally, as gene-centric models of disease have started to take hold, understanding the underlying functional mechanisms that are affected can help us elucidate the effect on molecular and cellular phenotypes that are regulated by KAT6B (Klein et al., 2019;Sheikh et al., 2012). We developed a model of KAT6B truncating variants in a human cell line to explore how these variants result in differential regulation of key transcripts. These types of approaches have been performed in a high throughput manner for tumor suppressor genes like BRCA1 (Findlay et al., 2018) and TP53 (Kotler et al., 2018) and can help identify key pathways that are dysregulated by KAT6B-related disorders and could be future targets for translational research. > Here, we analyze 20 clinical cases representing a KAT6B-related clinical spectrum across three domains: their genotype, phenotype, and experience with genetic counseling resources. Furthermore, we developed an in vitro model of KAT6B mutations using CRISPR technology to explore the effect of protein truncation on global transcriptional regulation. Here we demonstrate that the genes that drive core clinical phenotypes are enriched in our in vitro model system. Together, we show that our clinical observations parallel the transcriptional processes in our cell model systems which allow for a further understanding of the mechanisms underlying the KAT6Brelated clinical spectrum.

[3] Mechanistic Models of Signaling Pathways Reveal the Drug Action Mechanisms behind Gender-Specific Gene Expression for Cancer Treatments

  • Authors: C. Çubuk, F. Can, M. Peña-Chilet, J. Dopazo
  • Year: 2020
  • Venue: Cells
  • URL: https://www.semanticscholar.org/paper/e40f7a3b8f72ba01374ba00fbf308a47a3fa5dd4
  • DOI: 10.3390/cells9071579
  • PMID: 32610626
  • PMCID: 7408716
  • Citations: 9
  • Summary: Despite the existence of differences in gene expression across numerous genes between males and females having been known for a long time, these have been mostly ignored in many studies, including drug development and its therapeutic use. In fact, the consequences of such differences over the disease mechanisms or the drug action mechanisms are completely unknown. Here we applied mechanistic mathematical models of signaling activity to reveal the ultimate functional consequences that gender-s...
  • Evidence snippets:
  • Snippet 1 (score: 0.363) > Therefore, a proper interpretation of the effect that differences in gene expression have over phenotypes, such as drug response or disease progression, involves understanding the mechanisms of the disease or the mode of action of drugs, which can be interpreted through mechanistic models of cell signaling [12] or cell metabolism [13]. Mechanistic models have helped to understand the disease mechanisms behind different cancers [14,15], including neuroblastoma [16,17], breast cancer [18], rare diseases [19], complex diseases [20], the mechanisms of action of drugs [21,22], and other biologically interesting scenarios such as the molecular mechanisms that explain how stress-induced activation of brown adipose tissue prevents obesity [23] or the molecular mechanisms of death and the post-mortem ischemia of a tissue [24]. Among the few available proposals of mechanistic modeling algorithms that model different aspects of signaling pathway activity, Hipathia has demonstrated having superior sensitivity and specificity [12]. > Here, we propose the use of mechanistic models [13,14] of signaling activity related with cancer hallmarks [25], other cancer-related signaling pathways, and some extra relevant cellular functions to understand the functional consequences of the gender bias in gene expression. Such mechanistic models use gene expression data to produce an estimation of profiles of signaling or metabolic circuit activity within pathways [13,14]. An interesting property of mechanistic models is that they can be used not only to understand molecular mechanisms of disease or of drug action but also to predict the potential consequences of gene perturbations over the circuit activity in a given condition [26]. Actually, in a recent work, our group has successfully predicted therapeutic targets in cancer cell lines with a precision over 60% [15]. Therefore, we will use this mechanistic framework to understand what is the molecular basis of the different effects of cancer drugs by directly simulating their effect in the patients. This approach has recently been used by us to understand the generation of resistances in cancer at the single cell level in glioblastoma [27].

[4] Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

  • Authors: H. Breiteneder, Z. Diamant, T. Eiwegger, W. Fokkens, C. Traidl‐Hoffmann et al.
  • Year: 2019
  • Venue: Allergy
  • URL: https://www.semanticscholar.org/paper/e19b0755c4f4903f68377333676edebf9bd73c89
  • DOI: 10.1111/all.13851
  • PMID: 31056763
  • PMCID: 6973012
  • Citations: 90
  • Influential citations: 3
  • Summary: Recent developments in research and patient care and future trends in the discipline are reviewed and topics on food allergy, biologics, small molecules, and novel therapeutic concepts in allergen‐specific immunotherapy for airway disease are highlighted.
  • Evidence snippets:
  • Snippet 1 (score: 0.360) > The past decades have witnessed extensive progress in unraveling cellular and molecular mechanisms of immune regulation in asthma, allergic diseases, organ transplantation, autoimmune diseases, tumor biology, and chronic infections. 1,2 Consequently, a better understanding of the functions, the reciprocal regulation, and the counterbalance of subsets of immune and inflammatory cells but also structural cells-for example, epithelial and vascular cells, airway smooth muscle cells, neuroendocrine system-that interact via various intercellular messengers will indicate avenues for immune interventions and novel treatment modalities of allergic diseases and immunological disorders. It is generally expected that drug development in the next decades will show a significant shift from chemicals to biologicals. > After more than 20 years without any breakthrough drug becoming available for patients, several disciplines including allergology are now experiencing extraordinary times with the recent licensing of several major biological drugs and novel allergen-specific immunotherapy (AIT) vaccines. Several biological modifiers of the immune response targeting intracellular messengers or their receptors have been developed to date. [3][4][5][6][7][8] In addition, a number of promising small molecule drugs and vaccines are in the development pipeline. [9][10][11] This new era is now calling for the development of biomarkers and phenoand endotyping of diseases for customized patient care, which is termed stratified medicine, precision medicine, or personalized medicine. 4 Distinguishing phenotypes of a complex disease covers the observable clinically relevant properties of the disease but does not show a direct relationship to disease etiology and pathophysiology. In a complex condition, such as asthma, different pathogenetic mechanisms can induce similar clinical manifestations; however, they may require different treatment approaches. 12,13 These pathophysiological mechanisms underlying disease subgroups are addressed by the term "endotype." [12][13][14] Classification of complex diseases based on the concept of endotypes provides advantages for epidemiological, genetic, and drug-related studies. Accurate endotyping by using reliable biomarkers reflects the natural history of the disease and aims to predict the response to (targeted) treatments. 15 Recent studies have focused on better understanding

[5] The evolving burden of asthma and contemporary advances in management: Implications for clinical practice in Southern Africa

  • Authors: A. Kiboneka
  • Year: 2020
  • Venue: Unknown venue
  • URL: https://www.semanticscholar.org/paper/0ba536bc7dbea898dcaabe247c92c7897c7e059c
  • DOI: 10.30574/wjarr.2020.8.3.0315
  • Citations: 1
  • Summary: The development of novel asthma phenotyping & endo typing plus better classification of patients using machine learning and big data have markedly improved asthma treatment outcomes in both children and Adults, and several research groups have developed cluster analyses of phenotypes in severe asthma.
  • Evidence snippets:
  • Snippet 1 (score: 0.360) > Research Program (SARP) I and II cohorts to study mechanisms differentiating severe from non-severe asthma. SARP investigators characterized severe asthma as a heterogeneous syndrome with diverse molecular, biochemical, and cellular inflammatory features and structure-function abnormalities. > Adults and children with severe asthma were further categorized by unbiased statistical methods into clusters based on distinguishing clinical features. These studies have not been done in Sub-Sahara Africa. Research performed over the past one to two decades has sought to better understand the heterogeneous clinical nature of asthma. Whereas older attempts at phenotyping asthma emphasized the duality of allergic vs. non-allergic asthma, more recent non-biased analyses have attempted to cluster patients by a multitude of possible features, including age of onset, atopy, severity of airways obstruction, and requirement for medication. Examples of these phenotypes include early-onset mild allergic asthma, later-onset asthma associated with obesity, and severe non-atopic asthma with frequent exacerbations. The elucidation of asthma phenotypes has been further refined by including information regarding pathophysiologic mechanisms present in different groups. These groups, called endo-types, include examples such as aspirin-exacerbated respiratory disease and allergic bronchopulmonary mycosis. > A phenotype covers the clinically relevant properties of the disease, but does not show the direct relationship to disease etiology and pathophysiology. Different patho-genetic mechanisms might cause similar asthma symptoms and might be operant in a certain phenotype. These putative mechanisms are addressed by the term 'endotype'. > Classification of asthma based on endo-types provides advantages for epidemiological, genetic, and drug-related studies. A successful definition of endo-types should link key pathogenic mechanisms with the asthma phenotype. Thus, the identification of corresponding molecular biomarkers for individual pathogenic-mechanism underlying phenotypes or subgroups within a phenotype is important. > The term asthma encompasses a disease spectrum with mild to very severe disease phenotypes whose traditional common characteristic is reversible airflow limitation. Unlike milder disease, severe asthma is poorly controlled by the current standard of care.

[6] The Diabetes Syndrome – A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms

  • Authors: A. W. Rachfal, S. Grant, S. Schwartz
  • Year: 2021
  • Venue: International Journal of General Medicine
  • URL: https://www.semanticscholar.org/paper/4c088a6a8b613c15e817f7491d24022497b7f5c4
  • DOI: 10.2147/IJGM.S305156
  • PMID: 33776471
  • PMCID: 7987256
  • Citations: 6
  • Summary: The “Diabetes Syndrome”, an overarching group of interrelated conditions linked by these overlapping mechanisms, can be viewed as a conceptual framework that can facilitate understanding of the inter-relationships of superficially disparate conditions.
  • Evidence snippets:
  • Snippet 1 (score: 0.359) > Although many pathways lead to hyperglycemia in diabetes -the so-called "Egregious Eleven" (Listed in Table 1) -β-cell dysfunction is the core defect. 1,2 Four basic pathophysiologic mechanisms damage the β-cell, namely, genes and epigenetic changes, inflammation, an abnormal environment [especially fuel excess], and insulin resistance (IR). 1,2 2][3] The interplay between these pathophysiologic mechanisms influences the specific risk of development and progression of complications in an individual patient. [6][7][8][9][10][11][12][13][14][15] In clinical practice we often encounter these common diseases, frequently within one individual patient and they are treated as independent conditions. However, we believe their epidemiologic associations is, in part, due to the same underlying pathophysiologies driving β-cell damage and diabetic complications. That is, the same pathophysiologic mechanisms that damage the β-cell and promote diabetesspecific complications also have key roles in the pathogenesis of these diseases. ][9][10][11][12][13][14][15] However, we propose these connections go beyond mere epidemiologic links due to overlapping pathophysiology. In fact, these conditions occur together in enough frequency and have common overlapping pathophysiologic drivers that we have created a conceptual framework called "The Diabetes Syndrome". The name is inspired by the Greek meaning of syndromē (sun-[together] + dramein [to run]) as the conditions, indeed, run together (Figure 1). This article will describe the shared pathophysiologic and etiologic factors across these prevalent and related diseases within the Diabetes Syndrome conceptual framework discussed within the context of the 4 basic pathophysiologic mechanisms -genes and epigenetic changes, abnormal environment, inflammation, and IR -with a focus on commonalities between these diseases and DM. In brief, genetics can mediate susceptibility to damage from abnormal external and internal environmental factors, including inflammation and IR. All these mechanisms can promote epigenetic changes.

[7] Transcriptional profiling of Hutchinson-Gilford progeria patients identifies primary target pathways of progerin

  • Authors: Sandra Vidak, Sohyoung Kim, Tom Misteli
  • Year: 2026
  • Venue: Nucleus
  • URL: https://www.semanticscholar.org/paper/4bd99b0875508364d8672b6da5a50d024d485a53
  • DOI: 10.1080/19491034.2025.2611484
  • PMID: 41489464
  • PMCID: 12773485
  • Summary: To probe the clinical relevance of previously implicated cellular pathways and to address the extent of gene expression heterogeneity between patients, transcriptomic analysis of a comprehensive set of HGPS patients finds misexpression of several cellular pathways, including multiple signaling pathways, the UPR and mesodermal cell fate specification.
  • Evidence snippets:
  • Snippet 1 (score: 0.357) > Oxidative stress represents another key pathogenic mechanism in HGPS, as impaired NRF2 activity or increased reactive oxygen species (ROS) levels are sufficient to recapitulate HGPSassociated phenotypes [17,32,60]. Collectively, these findings underscore the multifactorial nature of HGPS pathogenesis, implicating interconnected signaling cascades involved in inflammation, oxidative stress, proteostasis, and vascular remodeling. Reassuringly, our findings indicate that many of the major pathways that have been described to contribute to HGPS phenotypes in mouse and cellular disease models are also misregulated in progeria patients, and targeting these pathways may provide therapeutic avenues to mitigate disease severity and improve outcomes in HGPS. > Although individuals with HGPS typically exhibit a characteristic set of clinical features, such as craniofacial abnormalities, growth retardation, and cardiovascular complications, there is notable variability in the age of onset, severity, and progression of symptoms between patients [7,9]. At the cellular level, HGPS is associated with several hallmark abnormalities, including nuclear envelope defects, decreased expression of several nuclear proteins and epigenetic marks, mitochondrial dysfunction, and increased cellular senescence [1,11,30,31,61]. These cellular phenotypes also exhibit considerable variation between patients, possibly contributing to differences in clinical outcomes. Our results indicate that even though some degree of transcriptional heterogeneity between the individual patients exists, the majority of patients exhibit misregulation of a set of shared pathways, suggesting that these pathways are universal driver mechanisms in HGPS. Further work is needed to understand the molecular and genetic factors that underlie inter-individual variability in disease expression and progression. > A limitation of pathway analysis of HGPS patient samples is to distinguish the pathways which are directly targeted by the disease-causing progerin protein and the emergence of adaptive secondary response pathways during progression of the disease in patients during their lifetime. The same caveat applies to the use of cell-based models used in the study of HGPS disease mechanisms.

[8] Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers

  • Authors: Chuanxin Liu, Hetao Chen, Yujin Ma, Lei Zhang, Lulu Chen et al.
  • Year: 2025
  • Venue: Frontiers in Endocrinology
  • URL: https://www.semanticscholar.org/paper/36f8d26a208b7b96763df2e9aa3211e440031c0e
  • DOI: 10.3389/fendo.2025.1501305
  • PMID: 40070584
  • PMCID: 11893406
  • Citations: 11
  • Summary: The results facilitate understanding the pathophysiology and mechanism of type 2 diabetes mellitus and supports research in accurate diagnosis, risk prediction, curative effect, distinct stages, and prognosis judgment of T2DM.
  • Evidence snippets:
  • Snippet 1 (score: 0.356) > The metabolome is sensitive to a variety of genetic and environmental stimuli and susceptible to genetic, environmental, and gut microbiome pressures, so subtle differences between individuals can lead to large perturbations in metabolite concentrations and fluxes (15, 24). At present, cystatin C has become an ideal endogenous marker for evaluating glomerular filtration function because it is not affected by sex, age or muscle mass (25). In addition, more and more evidence shows that serum CysC is involved in the pathological process of vascular remodeling and neovascularization, which is closely related to the occurrence and development of diabetic microangiopathy (26). > Eighty-four papers were included in this review and obtained through database searches, namely, PubMed, Cochrane Library, China national knowledge internet(CNKI), General Purpose, and VIP Database. The keywords for the searches were "metabolomics" and "type 2 diabetes mellitus" and its complications. The papers were incorporated by reading and summarizing the literature according to the classification standards (27). The profound analysis of clinical differential metabolites identified in type 2 diabetes and its complications were conducted concerning composition, frequency of category, sample type, and pathways to explore the pathological mechanism of type 2 diabetes and its complications to provide a systematic basis for clinical diagnosis, risk stratification, comprehending disease progression, prognosis assessment, and drug efficacy. Our goal is to apply metabolomics to clinical diagnostic biomarkers, metabolic mechanisms, and prognostic observations, and early diagnosis can be made through metabolites to avoid progression to more serious complications.

[9] A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach

  • Authors: Lina A. Dahabiyeh, M. Mujammami, T. Arafat, H. Benabdelkamel, A. Alfadda et al.
  • Year: 2021
  • Venue: Frontiers in Pharmacology
  • URL: https://www.semanticscholar.org/paper/072dece85121c66abd1a380c68a8ff465654eeea
  • DOI: 10.3389/fphar.2021.705932
  • PMID: 34335266
  • PMCID: 8319764
  • Citations: 32
  • Influential citations: 1
  • Summary: The distinctive metabolic pattern linked to metformin administration can be used as a metabolic signature to predict the potential effect and mechanism of actions of new chemical entities during drug development.
  • Evidence snippets:
  • Snippet 1 (score: 0.354) > Several disordered and complications are controlled and improved by metformin, including; metabolic and reproductive abnormalities of polycystic ovary syndrome (PCOS), cardiovascular complications associated with diabetes, cancer prognosis, and neurodegenerative diseases (Viollet et al., 2012;Rotermund et al., 2018;Foretz et al., 2019). Additionally, clinical studies have shown that metformin has beneficial effects on systemic inflammatory markers (Cameron et al., 2016) and weight loss in insulin-sensitive and insulin-resistant overweight and obese patients (Seifarth et al., 2013). > The pleiotropic properties of metformin and its numerous therapeutic areas suggest that various underlying mechanisms and metabolic pathways could be involved. Despite being introduced into the market for over 60 years, the mechanism of action of metformin remains partially explored and understood (Viollet et al., 2012;Foretz et al., 2014;Foretz et al., 2019). This urges the need for new and considerable efforts to understand better the cellular and molecular mechanisms of action of metformin. > Metabolomics is the comprehensive analysis of a set of small molecules (i.e., amino acids, lipids, and carbohydrates), referred to as metabolites within cells, biofluids, tissues, or organisms. It is a powerful analytical tool that is widely used to provide rich mechanistic information on drugs, and aid in identifying potential biomarkers that can be used to monitor the efficacy of drug therapies (Balashova et al., 2018;Jacob et al., 2019;Dahabiyeh et al., 2021). Pharmacometabolomics is an effective approach to capture the metabolic signatures linked to drug exposure and, therefore, improves the understanding of their underlying mechanisms of actions and allows individual differences recognition and drug toxicity prediction (Adam et al., 2016;Malkawi et al., 2018;Dahabiyeh et al., 2020).

[10] A Lifelike guided journey through the pathophysiology of pulmonary hypertension—from measured metabolites to the mechanism of action of drugs

  • Authors: Nathan Weinstein, Jørn Carlsen, S. Schulz, T. Stapleton, Hanne H. Henriksen et al.
  • Year: 2023
  • Venue: Frontiers in Cardiovascular Medicine
  • URL: https://www.semanticscholar.org/paper/0b2dc837dea11add7e2f67f06acf6280ac96a019
  • DOI: 10.1101/2023.11.21.23298782
  • PMID: 38845688
  • PMCID: 11153715
  • Citations: 3
  • Summary: The present study shows the power of mining knowledge graphs using Lifelike's diverse set of data analytics functionalities for developing knowledge-driven hypotheses on PH pathophysiological and drug mechanisms and their interactions.
  • Evidence snippets:
  • Snippet 1 (score: 0.353) > Pulmonary hypertension (PH) is a pathological condition that affects approximately 1% of the population. The prognosis for many patients is poor, even after treatment. Our knowledge about the pathophysiological mechanisms that cause or are involved in the progression of PH is incomplete. Additionally, the mechanism of action of many drugs used to treat pulmonary hypertension, including sotatercept, requires elucidation. Using our graph-powered knowledge mining software Lifelike in combination with a very small patient metabolite data set, we demonstrate how we derive detailed mechanistic hypotheses on the mechanisms of PH pathophysiology and clinical drugs. In PH patients, the concentration of hypoxanthine, 12(S)-HETE, glutamic acid, and sphingosine 1 phosphate is significantly higher, while the concentration of L-arginine and L-histidine is lower than in healthy controls. Using the graph-based data analysis, gene ontology, and semantic association capabilities of Lifelike, led us to connect the differentially expressed metabolites with G-protein signaling and SRC. Then, we associated SRC with IL6 signaling. Subsequently, we found associations that connect SRC, and IL6 to Activin and BMP signaling. Lastly, we analyzed the mechanisms of action of several existing and novel pharmacological treatments for PH. Lifelike elucidated the interplay between G-protein, interleukin 6, activin, and BMP signaling. Those pathways regulate hallmark pathophysiological processes of PH, including vasoconstriction, endothelial barrier function, cell proliferation, and apoptosis. The results highlight the importance of SRC, ERK1, AKT, and MLC activity in PH. The molecular pathways affected by existing and novel treatments for PH also converge on these molecules. Importantly, sotatercept affects SRC, ERK1, AKT, and MLC simultaneously. The present study shows the power of mining knowledge graphs using Lifelike's diverse set of data analytics functionalities for developing knowledge-driven hypotheses on PH pathophysiological and drug mechanisms and their interactions. We believe that Lifelike and our presented approach will be valuable for future mechanistic studies

[11] Chemotherapy and Mechanisms of Resistance in Breast Cancer

  • Authors: A. Oliveira, R. E. Santos, F. F. O. Rodrigues
  • Year: 2012
  • Venue: Unknown venue
  • URL: https://www.semanticscholar.org/paper/502a86d8bcd7208be6f539fcceba631f82f25a7d
  • DOI: 10.5772/24629
  • Summary: The addition of adjuvant polychemotherapy in advanced breast cancer showed gain by controlling survival of micrometastases in patients with lymph nodes affected by cancer or not.
  • Evidence snippets:
  • Snippet 1 (score: 0.353) > The main reasons responsible for treatment failure in cancer patients are the mechanisms of drug resistance and emergence of disseminated disease (Terek et al, 2003). We identified two types of resistance most relevant to BC: primary resistance, which corresponds to the clinical situation where the patient showed no response to therapy, and secondary or acquired resistance in which, initially, there is an observed response and a subsequent failure of the treatment regimen (Kroger et al, 1999). Several mechanisms may cause the phenotype of multidrug resistance to chemotherapy drugs and are well characterized in in vitro experiments, including alterations in systemic pharmacology (pharmacokinetics and metabolism), extracellular mechanisms (tumor environment, multicellular drug resistance), and cellular mechanisms (cellular pharmacology, activation and inactivation of drugs, modification of specific targets and regulatory pathways of apoptosis) (Leonessa et al, 2003, Riddick et al, 2005. Identification of factors that affect cell metabolism, which are related to drug resistance, will enable the identification of which patients are at particular risk of treatment failure. Among the biochemical and molecular mechanisms of drug resistance, we stress: changes in the activity of topoisomerase II, alterations in the DNA repair mechanism, overexpression of P-glycoprotein; high intracellular concentrations of enzymes purification of cellular metabolism -among them enzymes the family of glutathione S-transferases (GSTs) and changes in the mechanisms of signaling via c-Jun N-terminal kinase 1 (JNK1) -and "apoptosis signal-regulating kinase (ASK1) required for activation of the" mitogenactivated protein (MAP kinases) in apoptosis and cellular restoration. These pathways are also mediated by proteins encoded by genes of GSTs (O'Brien, Tew, 1996;Burg, Mulder, 2002, L'Ecuyer et al, 2004). Different response rates to particular chemotherapy regimens, as observed in patient groups with the same biological characteristics and stage, suggest the existence of different mechanisms of drug resistance, probably induced by genetic alterations (Hayes, Pulford, 1995;O'Brien , Tew, 1996;Pakunlu et al, 2003). Among the mechanisms of purification of cellular metabolism involved in the

[12] Genome-scale mechanistic modeling of signaling pathways made easy: A bioconductor/cytoscape/web server framework for the analysis of omic data

  • Authors: Kinza Rian, Marta R. Hidalgo, C. Çubuk, M. M. Falco, C. Loucera et al.
  • Year: 2021
  • Venue: Computational and Structural Biotechnology Journal
  • URL: https://www.semanticscholar.org/paper/af786ba590cb9db62ff31318c785685ade68bfd9
  • DOI: 10.1016/j.csbj.2021.05.022
  • PMID: 34136096
  • PMCID: 8170118
  • Citations: 10
  • Summary: This work presents the implementation of a mechanistic model of cell signaling for the interpretation of transcriptomic data as an R/Bioconductor package, a Cytoscape plugin and a web tool with enhanced functionality which includes building interpretable predictors, estimation of the effect of perturbations and assessment of the effects of mutations in complex scenarios.
  • Evidence snippets:
  • Snippet 1 (score: 0.352) > Mechanistic models of signaling pathways provide a natural bridge from variations in genotype (at the scale of gene activity or integrity) to variations in phenotype (at the scale of cells, tissues or organisms) [1]. They are built over graphs that represent the biological knowledge of the complex functional relationships among proteins within the cell, as described in repositories such as KEGG [2], Reactome [3], WikiPathways [4], or other more specialized, such as Disease Maps [5]. Specifically, they provide a conceptual framework for the interpretation of gene expression or genomic variation data and their consequences over downstream processes and phenotypic responses, such as cell proliferation and death, which are particularly relevant for studying disease progression or drug response [6]. Mechanistic models have successfully been used to understand the disease mechanisms behind different cancers [7,8] (including neuroblastoma [9,10] and glioblastoma [11]) rare diseases [12,13], complex diseases such as diabetes [14] or obesity [15], the mechanisms of action of drugs [16] or gender-specific effects of drugs in cancer [17]. In addition to diseases, other scenarios have been studied, such as the molecular mechanisms of death and the post-mortem ischemia of a tissue [18] or the effects of nanoplastics on embryos and human induced pluripotent stem cells [19]. > One of the most important aspects of mechanistic models is that they convey the notion of causality and can, therefore, be used to predict the downstream consequences of perturbations of specific conditions [20]. Thus, the possibility of simulating the effect of a drug allowed a systematic in silico drug repurposing experiment in Fanconi Anemia [21] in which some of the drugs predicted were further validated [22]. Also recently, all the targeted drugs currently in clinical trials for testing treatment and prevention of COVID-19 [23] were predicted by means of a mechanistic model [24] of the COVID-19 disease map [25]. application of mechanistic modeling show how the simulation of drug inhibitions at single-cell level uncovers the molecular basis of the generation of resistance to

[13] Role of Transcriptomics in Precision Oncology

  • Authors: Ruby Srivastava
  • Year: 2024
  • Venue: Reports of Radiotherapy and Oncology
  • URL: https://www.semanticscholar.org/paper/0bd862558bbb7286336111d9dfd232b5f905d3d9
  • DOI: 10.5812/rro-142195
  • Citations: 4
  • Summary: : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding o...
  • Evidence snippets:
  • Snippet 1 (score: 0.351) > : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding of cancer and opened a precise perspective for tumor diagnostics and therapy. The use of these approaches has strengthened our understanding of disease pathophysiology and classifications at the molecular level, including specific interference with drug mechanisms of action. Still, it has limited added value in the clinical setting. The omics data on precision medicine include the application of data from genes, transcripts, and proteins for diagnosis, monitoring of diseases, risk factor determination, counseling, and development of novel therapeutics. Bioinformatics applications have expanded statistics-based analysis toward deriving molecular pathways and process models for characterizing phenotypes and drug action mechanisms. In this review, we will discuss transcriptomics and interference analysis that allows the identification of predictive biomarkers at the molecular level to test drug response and analyze the molecular process interface of disease progression-relevant pathophysiology and mechanism of action to propose predictive biomarkers.

[14] Modeling psychiatric disorders: from genomic findings to cellular phenotypes

  • Authors: Anna Falk, Vivi M. Heine, A. Harwood, Patrick F. Sullivan, M. Peitz et al.
  • Year: 2016
  • Venue: Molecular Psychiatry
  • URL: https://www.semanticscholar.org/paper/235b41240d78140de7ab06a3ad8a7d0b1bdff1a5
  • DOI: 10.1038/mp.2016.89
  • PMID: 27240529
  • PMCID: 4995546
  • Citations: 77
  • Influential citations: 2
  • Summary: The challenges for modeling of psychiatric disorders, potential solutions and how iPSC technology can be used to develop an analytical framework for the evaluation and therapeutic manipulation of fundamental disease processes are critically reviewed.
  • Evidence snippets:
  • Snippet 1 (score: 0.351) > The key challenge for iPSC-based disease modeling is to identify one or more relevant cellular phenotypes that accurately represent the disease pathophysiology. Increasing numbers of reports have demonstrated that for many diseases specific pathophysiology can be captured in human iPSC-based disease models. These range from cardiovascular disease, 44,45 cancer, 46,47 ocular disease, 48,49 diabetes mellitus 50,51 and neurological disorders of the brain. 52,53 Can the same approach be applied to complex psychiatric disorders? > The problem is that almost all psychiatric disorders are characterized by clinical signs and symptoms, but lack independent verification from objective biomarkers. Thus, how might these clinical phenotypes manifest themselves in terms of cell behavior? The identity of robust cellular 'readouts', which typify any psychiatric disorder, is a crucial unsolved problem and an area of intense study 54 (Table 2). When satisfactorily answered, this will herald a new degree of biological objectivity and quantification for the study of psychiatric disorders. > The aim is to find a single or small number of cell phenotypes or parameters that strongly associate with psychiatric disorders, and establish a cellular profile characteristic of cells derived from the general patient population. Although a consensus set of cellular phenotypes for psychiatric disorder is yet to be established, we can define some of their desired characteristics. First, cellular phenotypes have to relate to the biological pathways identified by genetics. Second, although there are many risk genes in disparate biological pathways, at some level, phenotypes should converge onto a much smaller grouping. Third, phenotypes need to be quantifiable. Finally, to be useful for drug development cellular phenotypes should be reversed by pharmacological treatment, although not necessarily by drugs in current use. > Although human iPSC-based approaches underrepresent the complexity of the human central nervous system, cellular phenotypes are likely to lie more proximal to molecular disease mechanisms than phenotypes seen at the level of a tissue or organism, 55 and thus may bypass compensatory homeostatic (2) Gene expression profiles of SCZ human iPSC neurons identified altered expression of many components of the cyclic AMP and WNT signaling pathways. > (3

[15] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

  • Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
  • Year: 2025
  • Venue: Journal of Veterinary Internal Medicine
  • URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
  • DOI: 10.1111/jvim.70139
  • PMID: 40492724
  • PMCID: 12150350
  • Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
  • Evidence snippets:
  • Snippet 1 (score: 0.351) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[16] New Insights into Mitochondria in Health and Diseases

  • Authors: Ya Li, Huhu Zhang, Chunjuan Yu, Xiaolei Dong, Fanghao Yang et al.
  • Year: 2024
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/23002a4ffabfd043f52c664f4d5acab85b8dcac0
  • DOI: 10.3390/ijms25189975
  • PMID: 39337461
  • PMCID: 11432609
  • Citations: 37
  • Summary: This overview outlines the various mechanisms by which mitochondria are involved in numerous illnesses and cellular physiological activities and provides new discoveries regarding the involvement of mitochondria in both disorders and the maintenance of good health.
  • Evidence snippets:
  • Snippet 1 (score: 0.350) > Mitochondria are essential organelles within cells, playing critical roles not only in energy metabolism but also in various cellular activities, such as cell differentiation, signal transduction, and apoptosis. Mitochondrial dysfunction is implicated in a range of diseases, including but not limited to diabetes and its complications, neurodegenerative disorders, myocardial ischemia-reperfusion injury, and heart failure. Therefore, investigating the structure and function of mitochondria as well as the mechanisms underlying mitochondrial dysfunction in disease contexts holds significant scientific and clinical importance. > Basic scientific research: Diseases manifest systemically and exhibit complexity; thus, it is imperative to understand mitochondrial structure at the molecular level along with known pathways while characterizing novel pathways that influence mitochondrial behavior and functionality. For instance, mapping genetic interactions among genes encoding mitochondrial proteins can elucidate interrelations between different aspects of mitochondrial function. The first focused map of mitochondria has been constructed in yeast models, revealing dense and significant connections among localization pathways distributed across various mitochondrial compartments [126]. > Disease diagnosis: A comprehensive understanding of the mechanisms governing mitochondrial dysfunction can facilitate the development of innovative diagnostic tools. By monitoring specific indicators related to mitochondrial function, earlier diagnosis of diseases associated with mitochondrial impairment becomes feasible. Employing nextgeneration sequencing technologies for analyzing the mitochondrial proteome aids in identifying novel proteins and pathways linked to mitochondria while enabling streamlined diagnostics alongside genetic counseling opportunities for patients with mitochondrial diseases [127]. > Drug development: Advancements in our comprehension of how mitochondria contribute to disease processes may promote targeted therapeutic strategies. For example, metformin-a widely used antidiabetic agent-has recently been repurposed as an anticancer drug; its combination with standard epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improves progression-free survival rates and overall survival outcomes for patients with advanced lung adenocarcinoma [125]. > Personalized medicine: Given that manifestations of mitochondrial dysfunction may vary among individuals, research into mitochondria provides a theoretical foundation for personalized medicine by allowing tailored treatment plans based on individual states of mitochondrial functionality [127].

[17] Precision Therapeutics in Lennox–Gastaut Syndrome: Targeting Molecular Pathophysiology in a Developmental and Epileptic Encephalopathy

  • Authors: Debopam Samanta
  • Year: 2025
  • Venue: Children
  • URL: https://www.semanticscholar.org/paper/455479c1bfbea7b90b73c109228f67c813d13888
  • DOI: 10.3390/children12040481
  • PMID: 40310132
  • PMCID: 12025602
  • Citations: 19
  • Influential citations: 1
  • Summary: A narrative review explores precision therapeutic strategies for LGS based on molecular pathophysiology, including channelopathies, receptor and ligand dysfunction, receptor and ligand dysfunction, cell signaling abnormalities, cell signaling abnormalities, synaptopathies, and the repurposing of existing medications with mechanism-specific effects.
  • Evidence snippets:
  • Snippet 1 (score: 0.350) > Lennox–Gastaut syndrome (LGS) is a severe childhood-onset developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, cognitive impairment, and distinctive electroencephalographic patterns. Current treatments primarily focus on symptom management through antiseizure medications (ASMs), dietary therapy, epilepsy surgery, and neuromodulation, but often fail to address the underlying pathophysiology or improve cognitive outcomes. As genetic causes are identified in 30–40% of LGS cases, precision therapeutics targeting specific molecular mechanisms are emerging as promising disease-modifying approaches. This narrative review explores precision therapeutic strategies for LGS based on molecular pathophysiology, including channelopathies (SCN2A, SCN8A, KCNQ2, KCNA2, KCNT1, CACNA1A), receptor and ligand dysfunction (GABA/glutamate systems), cell signaling abnormalities (mTOR pathway), synaptopathies (STXBP1, IQSEC2, DNM1), epigenetic dysregulation (CHD2), and CDKL5 deficiency disorder. Treatment modalities discussed include traditional ASMs, dietary therapy, targeted pharmacotherapy, antisense oligonucleotides, gene therapy, and the repurposing of existing medications with mechanism-specific effects. Early intervention with precision therapeutics may not only improve seizure control but could also potentially prevent progression to LGS in susceptible populations. Future directions include developing computable phenotypes for accurate diagnosis, refining molecular subgrouping, enhancing drug development, advancing gene-based therapies, personalizing neuromodulation, implementing adaptive clinical trial designs, and ensuring equitable access to precision therapeutic approaches. While significant challenges remain, integrating biological insights with innovative clinical strategies offers new hope for transforming LGS treatment from symptomatic management to targeted disease modification.

[18] Prioritizing Molecular Biomarkers in Asthma and Respiratory Allergy Using Systems Biology

  • Authors: Lucía Cremades-Jimeno, M. D. de Pedro, M. López-Ramos, J. Sastre, P. Mínguez et al.
  • Year: 2021
  • Venue: Frontiers in Immunology
  • URL: https://www.semanticscholar.org/paper/d8ca6e130adec2dfa39545eb1763827d9450e4f5
  • DOI: 10.3389/fimmu.2021.640791
  • PMID: 33936056
  • PMCID: 8081895
  • Citations: 12
  • Influential citations: 1
  • Summary: This study has enabled it to prioritize biomarkers depending on the functionality associated with each disease and with specific molecular motifs, which could improve the definition and usefulness of new molecular biomarkers.
  • Evidence snippets:
  • Snippet 1 (score: 0.349) > Firstly, the molecular characterization of the three pathophysiological processes of interest (respiratory allergy, allergic asthma, and nonallergic asthma) was performed using the Therapeutic Performance Mapping System (TPMS) technology (Anaxomics Biotech, Barcelona, Catalonia, Spain) (31). Briefly, systems biology generates models that are able to reproduce the behavior of a disease in a patient, thus identifying the key genes, proteins, or metabolites in the development of the disease. A dictionary has been created to translate clinical and medical terms into molecular biology data, effectively linking the molecular and the clinical words. This dictionary, called the Biological Effectors Database (BED), relates biological processes (adverse events of drugs, drug indications, diseases, etc.) with the proteins most closely associated with them. Thus, the dictionary acts as a translator of clinical phenotypes into terms comprehensible for protein networks, and conversely allows for the translation of molecular measures toward clinical outcomes. The BED is structured hierarchically, where the biggest level is the entire disease, which is divided into different pathophysiological molecular motifs, which in turn contain the proteins involved in the development of the disease. The motifs are classified into two levels depending on their respective implication, i.e. causal motifs, which are directly related to the onset or pathophysiology of the condition, and symptomatic (manifestative) motifs, which are a consequence of the disease. > In the present study, respiratory allergy, allergic asthma, and non-allergic asthma have been characterized at the molecular level. Therefore, the analysis of high throughput data by means of TPMS allows for identification of those proteins closely associated with the disease of interest and can provide a mechanistic rationale for their involvement. The effector proteins of the manifestative and causal molecular motifs of these three diseases have been identified through bibliographic review and curate data. Figure 1 summarizes the workflow used for this study.

[19] Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response

  • Authors: P. Mesdom, R. Colle, É. Lebigot, S. Trabado, Eric Deflesselle et al.
  • Year: 2020
  • Venue: Current Neuropharmacology
  • URL: https://www.semanticscholar.org/paper/79368e365458486de96794333613c12a6063bf54
  • DOI: 10.2174/1570159X17666191021141057
  • PMID: 31631822
  • PMCID: 7327943
  • Citations: 12
  • Summary: This review highlights the great and still underused potential of HDF, which stands out as a very promising tool in the understanding of MDD and AD mechanisms of action.
  • Evidence snippets:
  • Snippet 1 (score: 0.349) > Background: Human dermal fibroblasts (HDF) can be used as a cellular model relatively easily and without genetic engineering. Therefore, HDF represent an interesting tool to study several human diseases including psychiatric disorders. Despite major depressive disorder (MDD) being the second cause of disability in the world, the efficacy of antidepressant drug (AD) treatment is not sufficient and the underlying mechanisms of MDD and the mechanisms of action of AD are poorly understood. Objective The aim of this review is to highlight the potential of HDF in the study of cellular mechanisms involved in MDD pathophysiology and in the action of AD response. Methods The first part is a systematic review following PRISMA guidelines on the use of HDF in MDD research. The second part reports the mechanisms and molecules both present in HDF and relevant regarding MDD pathophysiology and AD mechanisms of action. Results HDFs from MDD patients have been investigated in a relatively small number of works and most of them focused on the adrenergic pathway and metabolism-related gene expression as compared to HDF from healthy controls. The second part listed an important number of papers demonstrating the presence of many molecular processes in HDF, involved in MDD and AD mechanisms of action. Conclusion The imbalance in the number of papers between the two parts highlights the great and still underused potential of HDF, which stands out as a very promising tool in our understanding of MDD and AD mechanisms of action

[20] Deciphering cellular states of innate tumor drug responses

  • Authors: Esther Graudens, V. Boulanger, Cindy Mollard, R. Mariage-Samson, Xavier Barlet et al.
  • Year: 2006
  • Venue: Genome Biology
  • URL: https://www.semanticscholar.org/paper/c79e62f4751e287a9527444fdeae83162022d48a
  • DOI: 10.1186/gb-2006-7-3-r19
  • PMID: 16542501
  • PMCID: 1557757
  • Citations: 135
  • Influential citations: 7
  • Summary: Molecular interaction networks are described that provide a solid foundation on which to anchor working hypotheses about mechanisms underlying in vivo innate tumor drug responses, and represent a starting point from which by-pass chemotherapy schemes may be developed for critical therapeutic intervention in CRC patients.
  • Evidence snippets:
  • Snippet 1 (score: 0.349) > to TOP1 inhibitors [20,22]. > Our current understanding of mechanisms associated with drug resistance has been furthered by investigating drugresistant cellular models created by exposing a parental population (yeast, bacteria, mammalian cell lines) to increasing concentrations of a cytotoxic agent [23][24][25][26]. It has been difficult, however, to translate these insights into clinically meaningful improvements in cancer treatment, suggesting that in vitro unicellular models may not be applicable to the in vivo situation or represent the disease in its entirety. For instance, in CRC, TOP1 mutations that decrease the formation of DNA cleavage complexes were identified [27], but their implication in clinical resistance was not confirmed. > Since the introduction of molecular genetics methods in clinical oncology, examination of individual mRNA/protein expression levels of drug target molecules provided complementary indications on the mechanisms involved. Thus far, however, only a limited number of clinical studies of drug resistance have focused on individual candidate genes and these used clinical samples exclusively derived from patients that were already treated with drugs. In CRC, such gene-bygene molecular biology studies have highlighted only a partial list of candidate genes [28][29][30][31][32][33]; some of these genes were shown to be involved in mechanisms altering drug metabolite potency, others are known to participate in increase of drug efflux or decrease of drug toxicity, or to participate in inhibition of apoptosis (for an overview, see [32][33][34][35][36][37]). It is unclear at present whether these mechanisms play a causative role in clinical drug resistance, and no comprehensive analysis of entire drug resistance pathways has been conducted. > Pharmacogenetics and pharmacogenomics approaches have been initiated to study the relationship between individual variations and drug response rates [38,39]. Genetic polymorphisms of specific genes were found to be associated with clinical outcomes in patients treated through chemotherapy, and amplification of genes encoding drug targets or transporters was shown to alter the sensitivity of cancer cells to a particular chemotherapy [40,41]. Finally, loss of heterozygosity at specific regions of chromosomes was identified in specific carcinoma, although its consequence in treatment outcome remains

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.